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Astrocytes rescue neuronal health after cisplatin treatment through mitochondrial 
transfer. 
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Chemotherapy-induced cognitive impairments are associated with neuronal 
mitochondrial dysfunction. Cisplatin, a commonly used chemotherapeutic, induces 
neuronal mitochondrial dysfunction in vivo and in vitro. Astrocytes are key players in 
supporting neuronal development, synaptogenesis, axonal growth, metabolism and, 
potentially, mitochondrial health. We tested the hypothesis that astrocytes transfer 
healthy mitochondria to neurons after cisplatin treatment to restore neuronal health.   
We used an in vitro system in which astrocytes with Mito-mCherry-labeled 
mitochondria were co-cultured with primary cortical neurons or neuronal stem cells 
damaged by cisplatin. Culturing primary cortical neurons with cisplatin depolarized 
the neuronal mitochondrial membrane potential and reduced neuronal survival. 
Cisplatin induced abnormalities in neuronal calcium dynamics characterized by 
increased resting calcium levels, reduced calcium responses to stimulation with 
potassium chloride (KCl), and slower calcium clearance. The same dose of cisplatin 
that caused neuronal damage did not affect astrocytic mitochondrial respiration or 
astrocyte survival. Co-culture of cisplatin-treated neurons with astrocytes was 
associated with the transfer of mitochondria from astrocytes to cisplatin-treated 
neurons leading to the restoration of neuronal mitochondrial membrane potential, 
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normalization of neuronal calcium dynamics, and increased neuronal survival. 
Furthermore, the neurons that had received astrocytic mitochondria, showed a 
resolution of calcium dynamics.  
Mitochondrial Rho-GTPase 1 (Miro-1) is an important protein for 
mitochondrial motility and transfer. We show that the siRNA-mediated knockdown of 
Miro-1 in astrocytes reduced mitochondrial transfer from astrocytes to neurons and 
prevented normalization of neuronal calcium dynamics. 
Based on these results we questioned if astrocytes transferred mitochondria to other 
types of neuronal cells as well, such as neuronal stem cells (NSCs). Neuronal stem 
cells are important for neurogenesis, gliogenesis, and proper cognitive function. For 
astrocytic mitochondrial transfer to NSCs, we used an in vitro system consisting of 
mouse cortical astrocytes with DsRed-labeled mitochondria that were co-cultured 
with mouse NSCs. We observed that astrocytes transferred mitochondria to NSCs 
treated with cisplatin thus expanding upon the breath of astrocytic mitochondrial 
transfer.  
In conclusion, we identified transfer of mitochondria from astrocytes to 
neurons and NSCs damaged by cisplatin. We propose that mitochondrial transfer by 
astrocytes is an important repair mechanism to protect neurons against the toxic 







Table of Contents 
Approval page ............................................................................................................ i 
Title page ................................................................................................................... ii 
Acknowledgements ................................................................................................... iii 
Abstract  .................................................................................................................... v 
Table of contents ..................................................................................................... vii 
List of Illustrations ..................................................................................................... xi 
Chapter 1: Introduction .......................................................................................... 1 
1.1 Mitochondrial damage and dysfunction in the context of cisplatin neurotoxicity .. 4 
1.1.1 Cisplatin: therapeutic effect ....................................................................... 4 
1.1.1.1 Molecular Mechanisms of cisplatin .......................................... 5 
1.1.2 Neurotoxicity as a result of cisplatin .......................................................... 7  
1.1.2.1 Auditory and Renal toxicity ....................................................... 8 
1.1.2.2 Peripheral Neuropathy .............................................................. 8 
1.1.2.3 Cognitive dysfunction ................................................................ 9 
Mature neurons ............................................................ 10 
Brain functional connectivity and structural networks ... 12 
Adult neurogenesis ...................................................... 13 
Neural stem cells and progenitors ................................ 15 
1.1.2.4 Potential for endogenous protection ....................................... 16 
1.1.3 Mitochondrial damage as a result of cisplatin ......................................... 17 
1.1.3.1 Structural damage .................................................................. 18 
1.1.3.2 Oxidative phosphorylation....................................................... 19 
viii 
 
1.1.3.3 Mitochondrial membrane potential .......................................... 20 
1.1.3.4 Ca2+ dynamics ........................................................................ 23 
1.1.3.5 Mitochondrial repair mechanisms ........................................... 25 
1.2 Astrocytes play a key role in neuroprotection and repair ................................ 26 
1.2.1 Origin, morphology, and activation states ............................................... 27 
1.2.2 The function of astrocytes in brain health ............................................... 28 
1.2.2.1 Development of new neurons ................................................. 29 
1.2.2.2 Neuronal synaptogenesis and synaptic activity ...................... 31 
1.2.2.3 Blood-brain barrier and Cerebral blood flow ........................... 33 
1.2.3 Astrocytes as neuroprotectors ................................................................ 36 
1.2.3.1 Glutamate toxicity .................................................................. 36 
1.2.3.2 Ischemic injury/Stroke ........................................................... 37 
1.2.4 Astrocytes and mitochondrial repair ........................................................ 39 
1.2.4.1 Role of Rhot-1/Miro-1 ............................................................ 41  
1.3  Summary ......................................................................................................... 43 
Chapter 2: Materials and Methods ....................................................................... 44 
2.1 Culture of rat cortical neurons, rat cortical astrocytes, mouse cortical neurons 
and mouse NSCs  ................................................................................................... 44 
2.2 Astrocyte transfections ...................................................................................... 46 
2.3 Analysis of neuronal survival ............................................................................ 47 
2.4 Analysis of mitochondrial membrane potential and mitochondrial transfer ....... 48 
2.5 Analysis of mitochondrial bioenergetics ............................................................ 49 
2.6 Co-culture of astrocytes and NSCs ................................................................... 50 
ix 
 
2.7 Calcium imaging ............................................................................................... 50 
2.8 Data Analysis .................................................................................................... 52 
Chapter 3: Astrocytes rescue neuronal health after cisplatin treatment through 
mitochondrial transfer .......................................................................................... 53 
3.1 Astrocytes improve neuronal survival after cisplatin treatment ......................... 54 
3.2 Astrocytes improve mitochondrial membrane potential of neurons damaged by 
cisplatin ................................................................................................................... 58 
3.3 Astrocytes transfer mitochondria to neurons damaged by cisplatin .................. 61 
3.4 Role of Miro-1 in mitochondrial transfer from astrocytes to neurons ................. 64 
3.5 Effects of cisplatin and astrocytes on neuronal calcium dynamics .................... 66 
3.6 Mitochondrial transfer underlies the beneficial effects of astrocytes on calcium 
dynamics in damaged neurons ............................................................................... 70 
3.7 Summary ........................................................................................................... 74 
3.8 Supplemental section: Astrocytes transfer mitochondria to neuronal stem 
cells ........................................................................................................................ 75 
3.8.1 Results ............................................................................................ 76 
3.8.2 Summary ......................................................................................... 89 
Chapter 4: Discussion .......................................................................................... 80 
4.1 Implications of mitochondrial transfer on neuronal health as a result of cisplatin 
treatment ................................................................................................................. 81 
4.2 Implications of mitochondrial transfer on NSC health as a result of cisplatin 
treatment ................................................................................................................. 84 
4.3 Mechanisms of mitochondrial transfer: TNTs, Miro-1, Myo10, and CD38 ......... 85 
x 
 
4.4 Potential signaling mechanism involved ........................................................... 87 
4.5 Astrocyte resiliency ........................................................................................... 87 
4.6 Translatability of the model ............................................................................... 89 
4.7 Future directions and concluding remarks ........................................................ 91 
Bibliography .......................................................................................................... 95 

















List of illustrations 
xi 
 
Figure 1.1: Astrocytes improve neuronal survival after cisplatin treatment 
Figure 1.2: Astrocytes improve mitochondrial membrane potential of neurons 
damaged by cisplatin 
Figure 1.3: Astrocytes transfer mitochondria to neurons damaged by cisplatin 
Figure 1.4: Role of Miro-1 in mitochondrial transfer from astrocytes to neurons 
Figure 1.5: Effects of cisplatin and astrocytes on neuronal calcium dynamics 
Figure 1.6: Mitochondrial transfer underlies the beneficial effects of astrocytes on 
calcium dynamics in neurons damaged by cisplatin 






Chapter 1: Introduction 
 
Mitochondria are double membrane bound organelles that are crucial for 
cellular health through multiple functions, including ATP production via oxidative 
phosphorylation, regulation of apoptosis, and Ca2+ signaling and buffering. 
Mitochondria have a unique evolutionary origin in that all are derived from a common 
ancestral organelle that evolved from an endosymbiotic bacterium possibly related to 
alpha-proteobacterium(Roger, Muñoz-Gómez, et al., 2017). From there the 
endosymbiotic bacterium integrated, evolved, and diversified into a permanent 
organelle that we know today as the “powerhouse” of the cell.  
Though mitochondria are necessary for the health and survival of all cells, 
neurons are particularly sensitive to the proper functioning of mitochondria. Both 
developing and mature neurons are critically dependent on mitochondria function to 
perform the complex and high energy demanding processes necessary for 
neurotransmission, plasticity and establishing membrane excitability(Schon & 
Manfredi, 2003). Neuronal stem cells and progenitors rely on mitochondria as well to 
regulate cell fate and differentiation.  
Mitochondrial dysfunction plays a key role in many neurological disorders 
such as Alzheimer's and Parkinson's disease but we have shown that it also plays a 
role in chemotherapy-induced neurotoxicity especially in the context of platinum-
based chemotherapeutics(Flippo & Strack, 2017; Schon & Manfredi, 2003). 
Platinum-based chemotherapeutics such as cisplatin are common treatments for 
various cancers including breast, testicular, bladder, cervical, ovarian, lung, head 
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and neck, and many other cancers. Cisplatin’s main method of action is binding to 
nuclear and mitochondrial DNA leading to bulky adducts. Mitochondria are 
particularly sensitive to alkylating chemotherapeutics like cisplatin, in part, due to a 
lack of mitochondrial DNA repair mechanisms that target DNA adducts(Bohr & 
Anson, 1999). These adducts cause various downstream negative effects on cellular 
health, particularly mitochondrial health, and eventually lead to apoptosis. Cisplatin 
is particularly toxic as it can cross the blood-brain barrier in high enough 
concentration to cause damage to mature and developing neurons. Clinically, 
cisplatin-induced neurotoxicity in the brain leads to neurological and cognitive 
dysfunction such as memory loss, mood disorders, and poor attention which is 
termed Cisplatin-induced cognitive impairment (CICI). Interestingly, cisplatin-induced 
neuronal damage does not necessarily lead to massive neuronal death, indicating a 
potential endogenous neuroprotective mechanism at least for neurons.  
Astrocytes are necessary for the function and maintenance of the central 
nervous system through the various interactions that astrocytes have with mature 
neurons, developing neurons, and surrounding glia. Astrocytes are well known to be 
critical for neuronal development and survival and emerging studies have shown that 
astrocytes play an important role in neuroprotection and repair. Astrocytes protect 
against neuronal glutamate toxicity, ischemic insult, and mitochondrial 
dysfunction(Almad & Maragakis, 2018; Z. Liu & Chopp, 2016b). Astrocytes are more 
resistant than neurons to some insults such as oxygen-glucose deprivation, 
glutamate toxicity, and cisplatin-induced toxicity. In terms of protecting and repairing 
neuronal mitochondrial dysfunction, astrocytes will transfer mitochondria to neurons 
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both following injury and, for some populations, as a form of maintenance(Davis et 
al., 2014; Hayakawa et al., 2016b). The mechanisms of how mitochondria are 
transferred are still not well understood but some key players have been identified. 
Mitochondrial Rho-GTPase 1 (Miro-1), a Rho-GTPase that couples mitochondria to 
microtubules for transport, is known to be involved in not only astrocytic 
mitochondrial transfer but other mitochondrial transfer models(Ahmad et al., 2014; 
Babenko et al., 2018b; Gao et al., 2019c). Decreasing Miro-1 activity is associated 
with a decrease in mitochondrial transfer and neuronal health(Gao et al., 2019b).  
Another mechanism for mitochondrial transfer involves astrocytic CD38 
((Hayakawa et al., 2016b)). CD38, an enzyme mainly present in glial cells, is 
involved in the synthesis of cyclic ADP-ribose (cADPR). In terms of mitochondrial 
transfer CD38 is a calcium messenger in mitochondria and is therefore involved in 
the production/secretion/release of highly functional mitochondria (Hattori et al., 
2017b; Hayakawa et al., 2016a).  
Despite the growing understanding of the importance of astrocyte-neuron 
interactions in neurological disorders much is still currently unknown about 
astrocyte-neuron interactions during cisplatin-neurotoxicity in the brain. Specifically, 
it is unknown if astrocytes improve neuronal health, especially mitochondrial health, 
in the presence of cisplatin and if the improvement is, in part, due to mitochondrial 
transfer to neurons. Furthermore, it is unknown how mitochondrial transfer from 
astrocytes to neurons effects neuronal functions and survival. This introduction will 
provide the necessary background for this dissertation. This dissertation will focus 
on understanding the endogenous neuroprotective activity of astrocytes to neurons 
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and NSCs with an emphasis on the role of mitochondrial transfer from astrocytes to 
neurons or NSCs damaged by cisplatin.  
 The primary focus of this dissertation is based upon: English, K., Shepherd, 
A., Uzor, N. et al. Astrocytes rescue neuronal health after cisplatin treatment through 
mitochondrial transfer. acta neuropathol commun 8, 36 (2020). 
https://doi.org/10.1186/s40478-020-00897-7. Material from this paper has been used 
with permission in several chapters of this dissertation.  This introduction will first 
dive into explaining (1) mitochondrial dysfunction in the presence of cisplatin 
neurotoxicity and then (2) how astrocytes play a key role as neuroprotectors and 
repairers.  
 
1.1 Mitochondrial damage and dysfunction in the context of 
cisplatin-induced neurotoxicity 
 
1.1.1 Cisplatin: Therapeutic effect 
Cisplatin is a commonly used chemotherapeutic for a wide range of cancers 
with particular effectiveness against germ cell line cancers(Dasari & Tchounwou, 
2014; Dietrich et al., 2006a). It was first synthesized in 1844 by M. Peyrone, but it 
did not gain recognition as a potential chemotherapeutic until the 1960s during 
investigations by Dr. Barnett Rosenberg(Rosenberg et al., 1965, 1969). It was the 
first FDA approved platinum compound for cancer treatments in 1978, though it had 
been discovered already to have cytotoxic side-effects in the early 1960s(Dasari & 
Tchounwou, 2014; Goodsell, 2006). By the time of FDA approval cisplatin was 
5 
 
known to show anticancer activity in solid tumors including ovaries, testes, and 
tumors of the head and neck(Cisplatin - National Cancer Institute, n.d.). Cisplatin 
anti-tumor activity has expanded to breast, lung, bladder cancer and other solid 
tumor cancers(Kelland, 2007b; Kilari et al., 2016b).  
1.1.1.1 Molecular mechanisms of cisplatin: Cis-diammine dichloroplatinum, 
also known as cisplatin, is a small molecule composed of a doubly charged platinum 
ion surrounded by four ligands, 2 amine and 2 chloride ions(Arnesano et al., 2015; 
Choi et al., 2015; Dasari & Tchounwou, 2014; Kelland, 2007a; McWhinney et al., 
2009; Rosenberg et al., 1969). Several membrane transporters have been 
investigated that could allow cisplatin to enter the cell. The Multiple Drug Resistance 
1 (MDR1) is a key transporter including analogous ATPase effluxes such as the 
multi-drug resistance-associated protein (MRP), and ATP7A and ATP7B. Other 
potential importers include Copper transporter receptor (CTR1), carriers in the 
Solute Carrier Family (SLCs), and the aquaporins AQP2 and AQP9(Blair et al., 
2009b; Kilari et al., 2016a; Kuo et al., 2007; Motohashi & Inui, 2013). Degradation of 
importers such as CTR1 is linked to increased resistance to cisplatin(Kilari et al., 
2016a; Siddik, 2003b).  
Once entering the cell, cisplatin becomes activated by displacing the chloride 
ions with water molecules resulting in a strong electrophile that can react with 
nitrogen donor atoms on nucleic acids(Delalande et al., 2005; Siddik, 2003a). The 
amine ligands form a stronger interaction with the platinum ion than the chloride 
ions, which form a good leaving group. The N7 atoms of guanine and adenine 
(purine bases) are the main binding sites for cisplatin and can lead to intrastrand or 
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interstrand DNA crosslinks, also known as adducts or lesions(Dzagnidze et al., 
2007; Siddik, 2003a). The crosslinks cause major distortions in DNA structures both 
causing either bending or even unwinding of the double helix(Siddik, 2003a).  
Cisplatin-induced DNA crosslinks are a predominant contribution to the 
cytotoxic effects of cisplatin. The reasoning is that DNA crosslink distortions impede 
the normal processes of DNA such as transcription and replication(Bernocchi et al., 
2015b; McWhinney et al., 2009). The impediment leads to a cascade that, usually, 
results in impaired cell division and apoptosis.  
Cisplatin attacks not only genomic DNA but also mitochondrial DNA(Lomeli et 
al., 2017). Mitochondrial DNA is potentially more sensitive to cisplatin attacks, and 
though the exact reasons are unknown, it has been suggested that mitochondrial 
DNA lacks a nucleotide excision repair pathway that is utilized by genomic DNA to 
repair DNA adducts(Bernocchi et al., 2015a; Dzagnidze et al., 2007; Roos & Kaina, 
2013). This means that the molecular cascades that lead to cytotoxicity are not only 
due to genomic DNA damage but also mitochondrial DNA damage, and 
subsequently mitochondrial structural and functional damage as will be explained in 
section 1.1.3 (Matsos & Johnston, 2019b; Zhao, Chen, Qi, et al., 2017). Though 
DNA damage is a known critical component of cisplatin toxicity and plays a large 
contribution, other downstream effects such as reactive oxygen species and 
alterations of Ca2+ signaling equally play important roles.  
Though cisplatin is still a widely used and effective chemotherapeutic, it has 
been well known to cause neurotoxicity and nephrotoxicity since the 
1960s(Rosenberg et al., 1969). Neurotoxicity and nephrotoxicity remain the major 
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dose-limiting toxic side effects of cisplatin(Latcha et al., 2016). Briefly, cisplatin 
nephrotoxicity is due to transport of cisplatin into renal epithelial cells leading to DNA 
injury and consequently cell death and initiation of inflammatory pathways. This 
damage leads to severe renal tubular damage and reduction in glomerular 
filtration(Volarevic et al., 2019). One underlying cause of damage to the renal 
system in the presence of cisplatin is damage to the mitochondria.  
An important underlying problem with cisplatin induced toxicity, specifically 
neurotoxicity, is mitochondrial dysfunction. We will next introduce neurotoxicity as a 
result of cisplatin and then discuss the damage that occurs in mitochondria in the 
context of cisplatin neurotoxicity. 
 
1.1.2 Neurotoxicity as a result of Cisplatin 
 
Cisplatin-induced central nervous system toxicity is of special clinical 
importance due to the large scope of health problems that arise. Case studies of 
cisplatin neurotoxicity began in 1970s and documented both peripheral and central 
nervous system toxicity(Aabo et al., 1998; Dasari & Tchounwou, 2014). These early 
case studies first reported on retinal and auditory toxicity due to cisplatin treatment. 
Reports in the early 2000s began to link cognitive dysfunction during chemotherapy 
treatments in patients treated with cisplatin to what is now known to be cisplatin-
induced cognitive deficits and more broadly chemotherapy-induced cognitive deficits 
for when alternative chemotherapeutics are given(Dietrich et al., 2006a; X. M. Wang 
et al., 2015b). Currently, the literature is ever expanding on the downstream 
negative outcomes due to cisplatin treatment on the central nervous system, and 
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particularly cisplatin damage to neurons as will be discussed in this section. We will 
first briefly describe cisplatin induced neurotoxicity in the auditory, retinal and 
peripheral systems before diving deeper into cisplatin neurotoxicity that underlies 
cognitive dysfunction. We will also discuss the potential for endogenous protective 
mechanisms in response to cisplatin damage in the brain.  
 
1.1.2.1 Auditory and Retinal toxicity: Briefly, cisplatin induces hearing loss 
through production of excessive reactive oxygen species (ROS) in the cells of the 
cochlea(Lu et al., 2019; Zong et al., 2017). Activation of transient receptor potential 
vanilloid (TRP) channels could lead to cochlear inflammation from ROS (Sheth et al., 
2017b). Another possible ROS contributor is from damage to the cochlea 
mitochondria (Sheth et al., 2017a). The hearing loss is bilateral and largely 
permanent, and incidence of hearing loss in children treated with cisplatin range 
from 22-77%(Kelland, 2007a). Retinal toxicity is an infrequent form of cisplatin-
induced neurotoxicity but still has been reported specifically for head and neck 
cancer patients treated with cisplatin-based chemotherapy(Dulz et al., 2017; Wilding 
et al., 1985). The severity of the toxicity is dose and frequency dependent, but the 
mechanisms of toxicity are not well known though there is also focus on 
mitochondrial damage of retinal ganglion cells.  
 
1.1.2.2 Peripheral Neuropathy: Cisplatin-induced peripheral neuropathy 
(CIPN) is one of the major limiting factors in cisplatin-based treatments. CIPN 
contributes to prolonged chemotherapy infusion times, dose reduction, treatment 
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delays and even cessation of treatment.(J. Ma, Kavelaars, et al., 2018) It occurs in a 
time and dose dependent manner. CIPN occurs in over 60% of cancer patients 
treated with platinum-based chemotherapeutics such as cisplatin or cisplatin 
derivatives (carboplatin, oxaliplatin). CIPN develops after cumulative doses above 
200 mg/m2(Amptoulach & Tsavaris, 2011; Gregg et al., 1992; McWhinney et al., 
2009). It is characterized by painful paresthesias (tingling, prickling or pins/needles 
feeling) and numbness mostly in the upper and lower extremities. As the treatment 
progresses the symptoms often worsen and may develop into neuropathic pain. 
Though the mechanisms are still being investigated, the underlying causes of CIPN 
are largely characterized by sensory neuronal, specifically axonal, neuropathy. 
Studies in the early 1990s found that in patient postmortem neural tissue, platinum 
levels were significantly higher in the dorsal root ganglia (DRG) compared to 
peripheral nerves, dorsal and ventral roots(Gregg et al., 1992). Further studies have 
linked damage to the DRG as a key driver of CIPN and though the types of damage 
are still be investigated there is currently a strong focus on cisplatin-induced 
mitochondrial damage.  
 
1.1.2.3 Cognitive dysfunction:  Cognitive dysfunction from cisplatin 
treatment is a predominant, though recently acknowledged, form of cisplatin 
neurotoxicity. Cisplatin-induced cognitive dysfunction is associated with a host of 
complications due to cisplatin damage. The complications include advanced aging 
which is associated with dementia/Alzheimer disease development, mood disorders 
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such as depression and fatigue, and memory and learning deficits(Chiang et al., 
2019; Manohar et al., 2014; Matsos & Johnston, 2019a; Vichaya et al., 2015c).  
Cisplatin is the most penetrating of the platinum derivatives in crossing the 
blood brain barrier. Gregg et al. found that in the frontal lobes and spinal cords of 21 
post-mortem patients treated with cisplatin the levels of platinum were around 0.37 
µg/g and 0.24 µg/g respectively(Gregg et al., 1992). Cisplatin in combination with 
radiation therapy targeted to the brain for head/neck cancers, can lead to an 
increase in cisplatin entry across the blood brain barrier (Charest et al., 2013; 
Stewart et al., 1994b). Once crossing the blood brain barrier cisplatin severely 
damages mature neurons, neural stem cells and neural progenitors which is one of 
the major underlying reasons for cognitive dysfunction.   
 
Mature neuronal damage: The accumulation of platinum in the brain is lower 
in comparison to peripheral structures; however, evidence shows that even low 
doses of cisplatin can injure mature neurons and neuronal stem cells.  
Andres et al. illustrated that in hippocampal neurons a dose of 0.1 µM 
cisplatin, too low to reduce neuroblastoma cell survival or proliferation, greatly 
reduced dendritic spines (visualized with GFP) and excitatory post-synaptic densities 
(labeled with PSD95) after 30 min in vitro(Andres et al., 2014a). A dose of 1 µM 
cisplatin caused a more rapid loss of dendritic spine density (roughly 15 min). There 
is also a gradual loss of dendritic arborization and branching from 4 to 24 h of 
cisplatin in hippocampal neurons in vitro(Andres et al., 2014a). After cisplatin 
damage with 0.1 µM for four hours the potential recovery of hippocampal dendritic 
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spines did not occur at either 24 h or at 5 days after removal of cisplatin in 
vitro(Andres et al., 2014a). This is interesting because during other types of damage 
such as chronic stress caused by corticotropin-releasing hormone, a hippocampal 
neuropeptide released during stress, dendritic spines are the first to rapidly recover 
despite being the first damaged in vitro (Y. Chen et al., 2008). This indicates that 
cisplatin not only quickly damages structures imperative for neurotransmission and 
neuronal function, but that the damage may be chronic or possibly irreversible. One 
explanation that Andres et al. offers for this damage is that cisplatin causes a 
decrease in BDNF expression in cultured hippocampal pyramidal neurons. BDNF 
not only stimulates intracellular signaling for neuronal survival, morphogenesis and 
plasticity, but it also boosts dendritic spine growth and integrity(F. Chen, Ardalan, et 
al., 2018; Nelson & Alkon, 2015). Though how cisplatin effects BDNF activity is 
unclear there could be an association with mitochondrial damage and decrease in 
energy which could affect transcription of not just BDNF but other important proteins 
as well (F. Chen, Ardalan, et al., 2018; F. Chen, Danladi, et al., 2018; Su et al., 
2014b). The type of cisplatin induced damage on hippocampal pyramidal neurons 
observed by Andres et al. has also been observed by Zhou et al. in pyramidal 
neurons of the cingulate cortex. Zhou et al. treated mice with 2.3 mg/kg of cisplatin 
per day for 3 cycles consisting of 5 daily injections followed by 5 days without 
injections which led to a cumulative dose of 34.5 mg/kg of cisplatin. From there it 
was found that cisplatin greatly decreased dendritic branching and spine density of 
pyramidal neurons in the cingulate cortex in vivo(W. Zhou et al., 2016b). It is strongly 
suggested that damage to dendritic structures comprises the key basis of the many 
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cognitive dysfunctions observed during cisplatin treatment in vivo, and an important 
underlying culprit could be mitochondrial damage.  It is known that dendritic 
branching, arborization and synaptic integrity is based upon neuronal activity such 
as neurotransmission(F. Chen, Danladi, et al., 2018; Rossi & Pekkurnaz, 2019; 
Sheng, 2017). Mitochondria will position themselves in areas of high activity to aid in 
not only providing energy via ATP but also for neurotransmission through Ca2+ 
regulation(Stephen et al., 2015a), (Chang et al., 2006; Lomeli et al., 2017; Todorova 
& Blokland, 2016). This means that cisplatin induced mitochondrial damage is a key 
factor in the reduction of dendritic health and consequently neuronal communication. 
 
Brain functional connectivity and structural networks: Cisplatin-induced 
damage to neuronal dendritic health and complexity is thought to result in negative 
alterations in brain structural networks and ultimately the functional brain 
connectome that are related to decline in cognitive function((Chiu et al., 2018b)). 
The term functional brain connectome describes the assessment of efficient 
integration of brain activity amongst different brain regions(Dennis & Thompson, 
2014; Eggermont, 2019). This assessment, usually illustrated as a map, provides 
insight into how well different regions work together to process information(Chiu et 
al., 2018a). The brain functional connectome is commonly measured with functional 
magnetic resonance imaging which allows evaluation of interactions between brain 
regions through brain mapping(Dennis & Thompson, 2014; M. H. Lee et al., 2013). 
Brain structural networks can be measured by structural MRI which measures 
volume and structural networks of different regions of the brain rather than brain 
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activity(O’Connor & Agius, 2015). Chiu et al. found that anesthetized cisplatin-
treated mice (2.3mg/kg/day) had decreased neuronal connectivity in comparison to 
control as measured with resting state functional magnetic resonance (rsfMRI)(Chiu 
et al., 2018a). This decrease in neuronal connectivity was associated with severe 
cognitive impairments examined via executive memory tasks such as the puzzle box 
test(Chiu et al., 2018a). This means that, in mice, cisplatin changes the interactions 
between brain regions ultimately leading to less functional processing of information 
and cognitive impairments.   
In humans, Amidi et al. found that in testicular cancer patients treated with 
cisplatin-based chemotherapy the global and local brain network was altered in 
comparison to healthy controls. The altered brain structural network was associated 
with poor overall cognitive performance and, since the study was longitudinal, overall 
cognitive decline(Amidi et al., 2017). 
The studies of Chiu et al. and Amidi et al. provide evidence that cisplatin 
decreases not only brain structural networks but also functional connectivity which is 
associated with the development of cognitive impairment.  
 
Adult neurogenesis: Another target of cisplatin neurotoxicity is neuronal stem 
cells (NSC) and neural progenitor cells (NPC). NSCs and NPCs proliferate unlike the 
post-mitotic mature neurons, which means they have an added sensitivity to cisplatin 
which blocks proliferation. This poses a serious problem for NSCs and specifically 




Adult neurogenesis is the process of generating new neurons in the adult 
brain from primarily NPCs in the neurogenic niches of the dentate gyrus and the 
subventricular zone. This process does not occur as frequently in the adult brain as 
it does in the younger brain, but it still contributes to many important functions. Adult 
neurogenesis in the hippocampus is important for learning and memory formation, 
including adding in new information to stored long-term memory (Lepousez et al., 
2015; Suárez-Pereira & Carrión, 2015). Another interesting fact is that adult 
hippocampal neurogenesis can have a positive effect on mood regulation specifically 
for stress and depression(Snyder et al., 2011).  
The thought behind learning and memory formation is that the addition of 
newborn neurons into the neuronal circuitry adds to the cognitive information, or 
engram, that stores the memory. The cognitive information is termed engram while 
the neuronal network that processes the cognitive information is termed neuronal 
circuitry (Rodríguez-Iglesias et al., 2019). Alternatively, neurogenesis in the adult 
hippocampus can also clear old memories to allow formation of new memories, and 
this is also thought to be due to the integration of the newborn neuron into older 
neuronal circuits (Deng et al., 2010). The process of integration whether to form or 
clear new memories is slow in the adult brain as adult newborn neurons develop 
slowly despite having significant effect of neural circuit plasticity 
(Beckervordersandforth, 2017a). Overall, though the exact process of how a 
memory is formed or cleared is unknown, the integration of newborn neurons is an 




Neural stem cells and neuronal progenitors: In the presence of cisplatin, 
NSCs and NPCs have decreased survival and mitochondrial dysfunction both in vivo 
and in vitro. NSCs are normally defined as a heterogenous population of 
committed/uncommitted stem cells but for this dissertation NSCs will be defined as 
Nestin/GFAP+ indicating a non-committed lineage, while NPCs, which are 
committed to the neuronal lineage, will be defined as DCX+, unless otherwise 
reported. I am following this definition since these markers are established in the 
literature to define these cell types(Boukelmoune et al., 2018a; Donega et al., 2014; 
Nicola et al., 2015; Shimada et al., 2012). Boukelmoune et al. found that NSC 
survival is significantly decreased in the presence of 0.5 µM and 1 µM cisplatin in 
vitro. Also, at 1 µM mitochondrial aerobic respiration was greatly decreased in NSCs 
along with depolarized mitochondrial membrane potential(Boukelmoune et al., 
2018d). The cells examined by Boukelmoune et al. were a heterogenous population. 
Boukelmoune et al. treated mice with 2.3 mg/kg of cisplatin for two cycles of 5 days 
and found that the DCX+ NPC population in both the dentate gyrus (DG) and 
subventricular zone (SVZ) was greatly decreased(Boukelmoune et al., 2018a). Chiu 
et al. found similar results where the DCX+ neural progenitor niches of the DG 
decreased by 70% and 30% in the SVZ region after treatment with 2.3 mg/kg of 
cisplatin in vivo(Chiu et al., 2017b). Chiu et al. did not report decreases in survival 
for Nestin+/GFAP+ NSCs also detected in the DG and SVZ regions in vivo. Another 
study by Hinduja et al. demonstrated that cisplatin reduced the DCX+ population by 
~80% in the DG in the adult rat(Hinduja et al., n.d.).  
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As with neurons, NSCs and NPCs experience severe mitochondrial 
dysfunction due to cisplatin damage. Similar to mature neurons, mitochondria are 
important for providing energy and contributing to proliferation, synaptogenesis and 
dendritic health of the newborn and immature neurons. For NSCs and NPCs, 
mitochondria are not only important for ATP generation but are also important 
regulators of neural stem cell fate decisions (Beckervordersandforth, 2017b; Khacho 
et al., 2019b). The NSC (Nestin/GFAP/Sox2+) commitment to the neuronal lineage 
instead of glial lineage is due to a metabolic switch about the source of ATP(Khacho 
et al., 2019a). Instead of predominately glycolytic to generate ATP, the NSCs will 
use mostly oxidative phosphorylation of the mitochondria which is the predominant 
ATP source for neurons(Khacho & Slack, 2017, 2018). The metabolic switch to 
oxidative phosphorylation accompanies changes to mitochondrial shape such as 
fragmentation of mitochondria(Khacho et al., 2016). This could mean that in the 
presence of mitochondrial dysfunction due to cisplatin NSC and NPCs fate decisions 
would be impaired and thus neurogenesis would be decreased in the cisplatin-
treated brain. This decrease in neurogenesis could contribute to the cognitive 
deficits that patient’s experience. 
 
1.1.2.4 Potential for endogenous neuroprotection: I have reviewed the 
damage as a result of cisplatin –induced neurotoxicity, specifically what occurs in 
mature neurons. Overall, cisplatin causes multiple forms of damage to mature 
neurons, NSCs and NPCs including severe mitochondrial damage that could 
underlie cognitive deficits in chemotherapy patients. Despite the severe functional 
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damage from cisplatin on mature neuronal cells, mature neuronal cell death in vivo 
has not been observed in comparison to proliferating NSCs or NPCs.  The damage 
to mature neurons appears to be limited to structural damage such as decrease in 
dendritic branching and spines, and mitochondrial dysfunction. Damage to dendritic 
branches is potentially associated with a decrease in the functional connectivity of 
the brain as observed when there is less communication after cisplatin(Andres et al., 
2014b). With that said, this damage does not appear to lead to neuronal death which 
could mean that protective mechanisms could be operative in vivo to prevent the 
final steps leading to neuronal death of the mature neuron. Furthermore, even 
though a large percentage of patients report cognitive deficits, many recover from 
those deficits, some as early as 6 months.  Interestingly, though neurons suffer 
much damage another important cell type, astrocytes, may not suffer as much as it 
is known from in vitro and in vivo studies that they are resilient to cisplatin (Chiu et 
al., 2017a; Dietrich et al., 2006b). Current literature points to astrocytes as 
endogenous protective cells which play a key role in neuroprotection including 
during cisplatin neuronal injury.   
 
1.1.3 Mitochondrial damage as a result of cisplatin 
 
An underlying mechanism that lies at the center of cisplatin-induced cognitive 
deficits and neuronal dysfunction is mitochondrial damage. Generally, decreases in 
mitochondrial health, as observed during cisplatin damage, leads to various 
downstream cascades that not only decreases neuronal and neuronal stem cell 
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function but can also lead to decrease in survival. This special organelle that powers 
so many unique processes crucial for the neuron appears to be a common target of 
cisplatin. This section will dive a little more into the implications of cisplatin induced 
damage to mitochondrial structure, mitochondrial membrane potential, oxidative 
phosphorylation, and calcium dynamics. We will also briefly discuss the inefficiency 
of mitochondrial DNA repair pathways in repairing cisplatin damage. Introducing and 
discussing these topics will provide context for later chapters that observe how 
cisplatin damages neuronal mitochondrial health. 
1.1.3.1 Structural damage: Mitochondrial damage as a result of cisplatin 
treatment leads to changes in mitochondrial morphology. Chiu et al. found that in 
synaptosomes from brains of cisplatin-treated mice the mitochondria were swollen 
and had abnormal cristae despite an intact outer membrane in comparison to non-
treated animals(Chiu et al., 2017a, 2018a). Lomeli et al. also reported a similar 
change in morphology in CA3 hippocampal neurons where mitochondrial 
degradation and vacuolization was also observed in vivo. The degradation included 
abnormal cristae where the inner membrane was severely damaged. This structural 
damage of the inner membrane and thus cristae and matrix are strongly connected 
with highly dysfunctional mitochondria(Lomeli et al., 2017). With that said, the exact 
mechanisms of how cisplatin damages the inner mitochondrial membranes is 
unknown though there are suggestions that reactive oxygen species could play a 




1.1.3.2 Oxidative phosphorylation: The most well-known function of 
mitochondria is ATP production through oxidative phosphorylation (oxphos) which 
utilizes oxygen to generate ATP. Oxidative phosphorylation is facilitated through the 
electron transport chain (ETC) and the byproducts of the Krebs Cycle (also known 
as the tricarboxylic acid cycle (TCA) and the citric acid cycle). The inner 
mitochondria membranes (the cristae) contain the ETC which consists of five protein 
complexes: NADH dehydrogenase (complex I), succinate dehydrogenase (complex 
II), cytochrome c reductase (Complex III), cytochrome c oxidase (Complex IV), and 
ATP synthase (Complex V)(Kann & Kovács, 2007a).  The protein complexes of the 
ETC work together for the generation of ATP through oxidative phosphorylation. The 
Krebs cycle occurs in the inner mitochondrial matrix. The Krebs cycle is a cyclical 
series of chemical reactions that uses acetyl-CoA to create important electron 
donors, NADH and FADH2, that can be used in the ETC. The electrons donated by 
the Krebs cycle products, NADH and FADH2, are used to power the pumping of 
protons from the negative inner mitochondrial membrane space to the 
intermembrane space(Roger, Muñ oz-Gó mez, et al., 2017). The pumping of protons 
from the inner mitochondrial membrane to the intermembrane space creates an 
electrical potential difference(Osellame et al., 2012). This difference is used to 
generate ATP in the final step where the electrons are accepted by oxygen. The 
mechanisms of how cisplatin interferes with oxidative phosphorylation is unknown 
but the degradation of the inner mitochondrial membranes, which house the ETC 
and creates the environment for the Krebs cycle, most likely plays a role(Lomeli et 
al., 2017).  
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Neurons and NSCs treated with cisplatin have impaired oxidative 
phosphorylation ((Boukelmoune et al., 2018b; Lomeli et al., 2017)). When measuring 
the oxygen consumption capacity of synaptosomes from cisplatin treated animals 
Chiu et al. found that there is a decrease in oxygen consumption, a measurable 
result of a functional ETC, indicating that aerobic respiration is dysfunctional in the 
presence of cisplatin, at least in the synaptosomes of mature neurons ex vivo(Chiu 
et al., 2017a). Boukelmoune et al. found similar results with NSCs in vitro in that 1 
µM cisplatin decreases NSC oxygen consumption and thus also aerobic respiration 
(Boukelmoune et al., 2018c).  
 
1.1.3.3 Mitochondrial membrane potential: As mentioned, the ETC creates 
a potential gradient that powers ATP synthase to make ATP. The potential gradient 
is due to charge separations across the inner mitochondrial membrane and 
essentially generates the driving force for protons and thus generate ATP(Joshi & 
Bakowska, 2011a; Zorova et al., 2018b). This potential is called the mitochondrial 
membrane potential (MMP) and it is not only an important indicator of mitochondrial 
metabolic activity, but also of overall mitochondrial health(Chang & Reynolds, 2006; 
Gottlieb et al., 2003; Qiao et al., 2016). The MMP of neuronal mitochondria is 
generally around -150 to 180 mV (in comparison to the cytosol)(Kann & Kovács, 
2007b). Cultured rat cortical neurons have an MMP of -139 mV at rest but can 
fluctuate between -108 mV and -158 mV depending on metabolic 
demand(Gerencser et al., 2012). In terms of metabolic activity, ATP synthase can 
rotate in a clockwise rotation which would lead to either the synthesis of ATP by 
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using the energy of the MMP or rotate in the counterclockwise rotation which would 
hydrolyze ATP and lead to the regeneration of the MMP(Zorova et al., 2018a). This 
is an indicator of metabolic activity because the hydrolysis of ATP to regenerate the 
MMP would indicate mitochondrial stress while the generation of ATP would indicate 
proper mitochondrial health(Chinopoulos, 2011). This dynamic also potentially 
indicates the importance of mitochondrial membrane potential since the recovery of 
the mitochondrial membrane potential in the presence of mitochondrial stress is 
based upon ATP hydrolysis, the breakdown of a crucial and necessary 
molecule(Zorova et al., 2018a).  
The expense of ATP to restore the mitochondrial membrane potential is 
understandable when considering not only its role in ATP synthesis but also, its 
overarching role in programmed mitochondrial autophagy (mitophagy) and cell 
death.  
Though the mechanisms that underlie MMP oscillations are elusive, one 
player is the mitochondrial permeability transition pore complex (MPTP) which plays 
a key role in the permeability of the inner mitochondrial membrane especially during 
sustained mitochondrial stress frequently associated with mitophagy or even 
apoptosis(Briston et al., 2017b; E Britti et al., n.d.; Sinha & D’Silva, 2014). Activation 
of the MPTP can allow dysregulated entry of small molecules leading to a loss of 
potential, osmotic imbalance and eventual mitochondrial degradation(Briston et al., 
2017a; Zorov et al., 2014). As activated MPTP is usually associated with harmful, 
sustained MMP (potentially depolarized) its association with normal, homeostatic 
fluctuations in MMP is viewed as limited to occasional occurrences. It is difficult to 
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determine the optimal values for the MMP as mitochondria can have transient states 
of polarization depending on metabolic activity such as the operation of the proton 
pumps and MMP discharge for ATP synthesis, and the level of mitochondrial activity 
differs based on cell types(Buckman & Reynolds, 2001; Joshi & Bakowska, 2011b; 
Perry et al., 2011). The consequences occur during sustained depolarization or 
hyperpolarization. On the one hand higher MMP, or a more hyperpolarized 
membrane, could indicate higher energy capacity of the inner mitochondrial 
membrane and potentially higher synthesis of ATP. On the other hand, this higher 
electric field is energetically expensive to maintain especially in the presence of 
necessary transport across the inner membranes(Rego et al., 2001; Suzuki et al., 
2018; Zorova et al., 2018a). Consequently, high MMP is a significant producer of 
ROS and thus sustained hyperpolarization could lead to a detrimental release of 
ROS which underlies not only mitophagy but even cellular apoptosis(Nowak, 2002b). 
Alternatively, low MMP could indicate the natural homeostatic result of ATP 
production and would require rejuvenation so transient depolarization is not 
necessarily associated with poor mitochondrial function. The problems begin to arise 
with sustained depolarization of the MMP. Sustained inappropriately low MMP would 
lead to impairment of ATP production, and low ROS production, which are natural 
byproducts of normal mitochondrial function. Polarized MMP states are tightly 
monitored by mitochondrial quality controls with the key players being PINK1 and 
Parkin (Ding & Yin, 2012; Sugiura et al., 2014). Sustained polarization, specifically 
depolarization, often leads down to the organelle autophagic pathway of mitophagy 
unless such quality systems are hampered as could be a possibility during cisplatin 
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treatment. Interestingly, cisplatin can cause a hyperpolarized and depolarized MMP 
state depending on the cell type. The mitochondria of epithelial renal cells have 
hyperpolarized MMPs after cisplatin in vitro which results in excessive ROS 
production while neurons and NSCs/NPCs are associated with depolarized MMP, 
and poor aerobic respiration after cisplatin treatment(Nowak, 2002a; Ying Wang et 
al., 2018; Zhao, Chen, Xu, et al., 2017). Boukelmoune et al. found that 1 µM cisplatin 
induced MMP depolarization in the mitochondria of NSCs after 12 hrs using the 
MMP monometric dye Tetramethylrhodamine (TMRM) in vitro(Boukelmoune et al., 
2018b). It is currently unknown how cisplatin damages mature neuronal MMP and 
this will be explored further in this dissertation.  
 
1.1.3.4 Ca2+ dynamics: Calcium is a crucial signaling molecule for 
neurogenesis and neuronal function. Specifically, mitochondrial calcium functions 
play important roles for neuronal survival and function(Gleichmann & Mattson, 2011; 
Kann & Kovács, 2007a; Smith & Gallo, 2018). Activated neurons have elevations in 
cytosolic Ca2+ due to entry through the plasma membrane via voltage gated Ca2+ 
channels and Ca2+ from intracellular stores such as through the ER(Kann & Kovács, 
2007c). This accumulation and subsequent release are suggested to be important 
for many neuronal specific functions and during injury. Mitochondrial Ca2+ release is 
primarily regulated by a Na+/Ca2+ exchanger and the rate of Ca2+ release is lower 
than the rate of uptake through the mitochondrial calcium uniporter (MCU) which 
means there is a continuous Ca2+ accumulation observed when cytosolic Ca2+ is 
high(Elena Britti et al., 2018; Pivovarova & Andrews, 2010b). When opened by 
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elevated cytosolic Ca2+, the MCU allows Ca2+ to flow into the mitochondrial matrix 
down an electrochemical gradient(Xu et al., 2016). Another method of Ca2+ entry into 
the mitochondria is through the voltage-dependent anion channels (VDACs). VDACs 
are porin-like proteins that line the mitochondrial outer membrane. They play many 
roles in energy conservation by allowing the entry of substrates for the TCA cycle 
(Brini et al., 2014; Pivovarova & Andrews, 2010c). VDACs play a role in allowing 
Ca2+ diffusion into the intermembrane space(Xu et al., 2016).  
Calcium is maintained within neuronal cytoplasm at a low concentration of 
around 50-100 nM to avoid negative effects such as phosphate precipitation(Brini et 
al., 2014; Pivovarova & Andrews, 2010a). To control calcium levels, cells 
compartmentalize calcium into mitochondria and the endoplasmic reticulum. Both 
organelles have a synergistic function and can form complexes (ER-mitochondrial 
tethering complex) to properly buffer Ca2+. At rest, most mitochondrial Ca2+ comes 
from the ER through close contact sites of the tethering complex called the 
mitochondrial-associated membranes (MAMs)(Bernard-Marissal et al., 2018; 
Pivovarova & Andrews, 2010c). At rest, the neuronal mitochondrial stores are quite 
low with a range of 0.1 mM to 100 nM Ca2+ stored in comparison to the endoplasmic 
reticulum(Brini et al., 2014). However, when neurons are activated mitochondria can 
store large amounts of Ca2+ in comparison to the endoplasmic reticulum with 
estimates of up to 600 nM(Pivovarova et al., 1999). Elevations in neuronal 
mitochondrial Ca2+ not only occur at the soma but also at synaptic clefts due to its 
necessity during neurotransmission. In this way mitochondrial Ca2+ uptake and 
release can modulate neurotransmitter release during stimulation in neurons and 
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lead to short-term plastic changes in the efficiency of neurotransmitter release(Vos 
et al., 2010). Moreover, clearance of cytosolic Ca2+ is equally important for neuronal 
health and Ca2+ is largely removed through ATP dependent activity such as the Ca2+ 
ATP-pump(Ivannikov et al., 2010; Marland et al., 2016).  
Currently, there is no literature explaining the effects of cisplatin on mature 
neuron- or NSC Ca2+ dynamics; however, it is known that damage to mitochondria 
alters neuronal Ca2+ dynamics particularly in neurodegenerative models such as 
Alzheimer’s disease(Magi et al., 2016; Supnet & Bezprozvanny, 2010). From this we 
could hypothesize that since cisplatin damages mitochondria, neuronal Ca2+ would 
be negatively altered as well. To start, since mitochondria are important for neuronal 
Ca2+ uptake, cisplatin-induced damage could lead to an inability for mitochondria to 
uptake large amounts of Ca2+ that are necessary for neurotransmission. Also, since 
many Ca2+ clearance mechanisms depend on ATP, and neurons rely heavily on ATP 
derived from mitochondrial oxphos, it could be inferred that mitochondrial damage 
could also lead to impaired Ca2+ clearance. In this dissertation I have explored some 
implications of cisplatin effects on neuronal Ca2+ in later chapters. 
 
1.1.3.5 Mitochondrial repair mechanisms: Mitochondrial DNA do not have 
a repair mechanism to remove cisplatin DNA adducts, unlike nuclear DNA (nDNA). 
Nuclear DNA has 6 repair pathways and 1 pathway, nucleotide excision repair 
(NER), is known to remove cisplatin DNA adducts in nDNA(Boesch et al., 2011; 
Larsen et al., 2005). The NER pathway is the most documented pathway being 
involved in the repair of cisplatin created DNA adducts. Defects in the NER pathway 
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lead to increased sensitivity to cisplatin(Katarzyna & Blasiak, 2002.; Rocha et al., 
2018).  
Cisplatin appears to preferentially bind to mitochondrial DNA (mtDNA) in 
comparison to genomic or nDNA in both cancerous and non-cancerous in vitro 
models (Dietrich et al., 2006b; Podratz et al., 2011; Yang et al., 2006). Mitochondrial 
DNA has a less efficient repair system than nDNA to repair cisplatin DNA adducts. 
Mitochondrial DNA has 5 repair pathways: base excision repair (BER), mismatch 
(MMR), double strand break repair (DSBR), direct repair (DR), and damage 
tolerance (DT)(Bohr & Anson, 1999; Kazak et al., 2012). One important missing 
pathway in the mtDNA repair system is the NER pathway that is present in nDNA, 
and it is still being investigated if a similar pathway is used by mitochondria. The 
closest possible pathway could be the BER but it is inefficient for repairing bulky 
adducts such as those caused by cisplatin and is normally relegated to smaller 
adducts or lesions(Bohr & Anson, 1999). This means that mtDNA is not only 
vulnerable to attack from cisplatin but also to irreparable, permanent damage, and 
this could underlie the reasons for the sensitivity of mitochondria to cisplatin 
damage.  
 
1.2 Astrocytes play a key role in neuroprotection and repair 
 
When first discovered, astrocytes were thought to be simply the “glue” that 
held the brain together and provide structural support to neurons(Bylicky et al., 
2018). It is now known that astrocytes are a heterogeneous population of glial cells 
that support, protect, and promote neuronal health throughout neuronal development 
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and maintenance, and repair after injury(Bayraktar et al., 2014; Bylicky et al., 2018). 
I will first briefly describe the basic morphology and function of astrocytes and their 
relationship with neurons. I will then describe some well-documented roles that 
astrocytes play as neuroprotectors or repairers during glutamate toxicity, stroke and 
mitochondrial dysfunction. 
 
1.2.1 Origin, morphology and activation states 
  
Astrocytes are the most abundant cell type in the brain and originate from the 
neuroepithelium(Bayraktar et al., 2014; Kriegstein & Alvarez-Buylla, 2009b). 
Astrocytes have a spongiform morphology and are divided into two main subclasses: 
protoplasmic and fibrous(Lundgaard et al., 2014; Yuan Liu, 2012). Protoplasmic 
astrocytes are found throughout all gray matter and display a stellate 
appearance(Bayraktar et al., 2014; Chaboub & Deneen, 2013; Yuan Liu, 2012). 
Fibrous astrocytes are found throughout white matter and have long fiber-like 
processes(Y. Liu et al., 2012; Lundgaard et al., 2014). Both subtypes have 
differences in their development and in the expression of receptors and proteins, but 
both still express the glial fibrillary acidic protein (GFAP), as well as calcium-binding 
S100B protein(Bayraktar et al., 2014; Mizuno et al., 2018). Another potential subset 
of astrocytes that is still being investigated are those found in the subventricular 
zone (SVZ) of the adult brain that express both GFAP, Nestin and carbohydrate 
Lewis X (LeX). This peculiar population displays stem-cell like features and gives 
rise to interneurons and oligodendrocyte precursors(Gonzalez-Perez & Quiñones-
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Hinojosa, 2012; Kriegstein & Alvarez-Buylla, 2009). It should be noted that GFAP 
and Nestin are also markers for neuronal stem cells which reside in the dentate 
gyrus. This population of astrocytic adult neural stem cells are still being questioned 
as belonging to the stem cell lineage, astrocyte lineage or if they represent some 
hybrid form(Ihrie & Alvarez-Buylla, 2008).  
The most pronounced activation state of astrocytes is known as astrogliosis 
or reactive astrogliosis and is observed in a variety of injuries to the brain and in 
response to inflammation or neurodegeneration. This activated state of astrocytes 
can perform a variety of tasks in response to injury. The tasks releasing molecular 
signals which trigger the transition of other astrocytes from quiescent to the activated 
state and stimulate astrocyte proliferation(Hamby & Sofroniew, 2010; Kang & 
Hébert, 2011; Sirko et al., 2015). Moreover, astrogliosis precludes the continued 
release of pro-inflammatory molecules and growth factors and this lasts until 
inhibitory molecules such as the anti-inflammatory cytokine IL-10 override the 
activation of the astrocyte(Anderson et al., 2014; Jensen et al., 2013; Pekny et al., 
2014; Sofroniew & Vinters, 2010). Once inhibited, astrocytes can return to their 
quiescent state but still maintain the permanent glial scar as observed during 
cerebral insults. The latter has been explained as a form of neuroprotection after 
injury such as stroke. Astrocytes do not become active in the presence of cisplatin, 
but it should be noted that cisplatin does not cause an increase in pro-inflammatory 
cytokines in the brain despite neuronal damage(Chiu et al., 2017).  
 




I will now discuss a few well-documented astrocytic functions including how 
astrocytes interact with neurons to promote synaptic integrity, activity and plasticity, 
as well as how astrocytes support the blood brain barrier and cerebral vasculature. I 
will then discuss how astrocytes can act as neuroprotectors in the context of 
abnormalities in the previously discussed functions. Another purpose to discussing 
these specific functions is that they will also provide necessary background to 
understand later chapters discussing the implications of this dissertation. These 
functions include how astrocytes interact with neurons and promote synaptic 
integrity, activity and plasticity,  
 
1.2.2.1 Development of new neurons: Astrocytes play a critical role in the 
development, migration, and integration of new neurons in the adult brain from the 
neurogenic niches. It should be noted that though there are astrocyte-like neural 
stem cells (Nestin/GFAP+) with neurogenic properties, there are also GFAP+ 
astrocytes within the neurogenic niches that have non-stem cell like properties and 
are thus “traditional” astrocytes(Gengatharan et al., 2016; Gonzalez-Perez & 
Quiñones-Hinojosa, 2012).  This section will discuss the non-neurogenic or 
traditional astrocytes. Astrocytes in both neurogenic niches, the SVZ and DG, are 
necessary to promote proliferation and neuronal stem cell fate. Song et al. explored 
that when GFP+ adult stem cells were co-cultured with adult hippocampal astrocytes 
or neonatal hippocampal astrocytes in vitro, there was an increase in MAP2+ 
neurons in comparison to co-culturing with adult spinal cord astrocytes or 
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fibroblasts(Song et al., 2002). This indicates that astrocytes from neurogenic niches 
appear to be primarily responsible for stem cell fate decision to neurons and 
promote neurogenesis. This is due to the morphogens that non-neurogenic 
astrocytes within the NSC niches release. Bone Morphogenetic Protein (BMP), 
Notch, Wnt, and Sonic Hedgehog (Shh) are important signaling factors secreted by 
astrocytes and influence NSC fate. (Gengatharan et al., 2016). Briefly, Wnt signaling 
is thought to promote neurogenesis while BMP signaling is thought to promote 
gliogenesis(Chavali et al., 2018; Cole et al., 2016; D. K. Ma et al., 2005a). Notch and 
Shh are thought to be involved in proliferation(Chandrasekaran et al., 2016; 
Gengatharan et al., 2016; Z. D. Zhou et al., 2010). Moreover, other astrocyte-derived 
factors such as IL-1β and IL-6 can influence promotion of neurogenesis or 
gliogenesis, but insulin-like-growth factor binding protein 6 (IGFBP6) can inhibit 
neurogenesis(Gengatharan et al., 2016; Islam et al., 2009; Taga & Fukuda, 2005). 
With that said, these are but a few known astrocyte-derived factors that work 
together to modulate NSC cell fate and the complex ways they interact under basal 
conditions or in the presence of insults are still being investigated(Barkho et al., 
2006). Ultimately, the complexity of astrocyte-derived modulators on NSC fate 
enhances the importance of astrocytes in the birth of new neurons or glial cells in the 
adult brain.  
Astrocytes are also important in neuronal migration and integrating new 
neurons into existing neuronal circuitry in the adult brain. In terms of the SVZ region, 
astrocytes can enshroud the DCX+ NPCs which migrate to the olfactory bulb (OB) in 
a chain-like formation through the rostral migratory stream (RMS)(Bozoyan et al., 
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2012; W. Sun et al., 2010). Briefly, the RMS is a migratory, tube-like pathway 
between the SVZ region and the olfactory bulb. The NPCs attach to the vasculature 
scaffolds that line the RMS to travel to the OB (W. Sun et al., 2010).  The RMS is 
developed and maintained by astrocytes, including the formation of the vasculature 
scaffolds(Bozoyan et al., 2012).  For new neurons born from both the SVZ and DG 
of the hippocampus, astrocytes are important for integration of the new neurons 
including maturation of synapses.  
 
1.2.2.2 Neuronal synaptogenesis and synaptic activity: Astrocytes provide 
many basic housekeeping functions for neurons and neuronal stem cells including 
the development and maintenance of neuronal synaptic integrity, a necessary 
function of neuronal health. Astrocytes are very important in guiding neuronal stem 
cells to their destinations during development and promoting synaptogenesis as the 
neuron matures(Kornack & Rakic, 1999; Y. Liu et al., 2012; Moss et al., 2016; W. 
Sun et al., 2010).  
During neonatal development neurogenesis occurs before astrogenesis and 
astrogenesis begins after birth (around P0) in mice. By E18/P0 neurons have 
elaborated their processes but it is not until astrocytes have matured that neuronal 
processes, particularly synaptic processes, also mature and become 
functional(Farhy-Tselnicker & Allen, 2018; Slezak & Pfrieger, 2003.). Astrocytes can 
not only influence synaptic strength but potentially the fate of synapses. Beattie et al. 
showed that astrocytes produce tumor necrosis factor alpha (TNF-α) which can 
enhance synaptic strength by increasing surface expression of AMPA receptors in 
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rat hippocampal neurons in vitro(Beattie et al., 2002). AMPA receptors are important 
glutamate receptors that allow the influx of Ca2+ into the synapse. Moreover, 
continued expression of astrocyte derived TNF-α is necessary to preserve synaptic 
efficiency and strength of excitatory synapses(Beattie et al., 2002; Stellwagen & 
Malenka, 2006). This is one example of how astrocytes can influence synaptic 
strength which is an important component of synaptogenesis as well as synaptic 
maintenance. The exact mechanism of how astrocytes eliminate synapses is still 
being deduced but there are studies that suggest that astrocytes can eliminate 
synapses. One suggested way that astrocytes could regulate synaptic fate is by 
withdrawing the release of maturation molecules such as TNF-α, thus causing the 
synapses to weaken(Allen, 2014). Another theory includes phagocytosis as 
astrocytes express phagocytic receptors such as receptors for MERKT which 
induces a phagocytic pathway(Jung & Chung, 2018; E. Lee & Chung, 2019).  
Astrocytic processes envelop pre- and post-synaptic terminals and create a 
tripartite synapse, a physical barrier that inhibits the release of neurotransmitters 
outside of the synaptic cleft. The tripartite synapse is a combination of the 
presynaptic terminal, post synaptic terminal and astrocytic processes. Within 
tripartite synapses astrocytes can modulate synaptic activity by releasing or taking 
up various transmitters or other factors. One example of how astrocytes modulate 
synaptic activity is through removing K+ ions to prevent K+ accumulation after 
neuronal activation. Preventing K+ accumulation leads to less neuronal 
hyperexcitability(Z. Liu & Chopp, 2016a). Another example is that astrocytes could 
release GABA which would lead to inhibition of neuronal depolarization(Le Meur et 
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al., 2012). Astrocytes can also modulate neuronal excitability through reuptake or 
release of glutamate(Harada et al., 2016). Glutamate is an important excitatory 
neurotransmitter and is one of the most abundant neurotransmitters in the 
brain(Bylicky et al., 2018; Kanki et al., 2004; Kasischke, 2015a; Voloboueva et al., 
2007). Astrocytes can not only release glutamate, which can activate presynaptic 
NMDA receptors, but also uptake excess glutamate and convert it to 
glutamine(Stephen et al., 2015b). The astrocytic converted glutamine is then 
recycled by neurons to create neurotransmitters such as glutamate or 
GABA(Mahmoud et al., 2019). 
Astrocytes can modulate neuronal plasticity including long term potentiation 
(LTP) and depression (LTD) through multiple mechanisms(Sofroniew & Vinters, 
2010). As previously mentioned, astrocytes can activate NMDA receptors, but 
astrocytes can also increase the density of NMDA and AMPA receptors in post-
synaptic neurons through release of TNF-α(Hahn et al., 2015; Kanki et al., 2004). 
The ability of astrocytes to regulate the NMDA receptor population means that 
astrocytes can regulate synaptic maturation and strength which can change 
neuronal activity. At the level of dendritic spines, which rapidly change in size to 
modulate LTP and LTD, astrocytes also rapidly communicate with spines and it has 
been suggested that this coordination can influence spine density(Clarke & Barres, 
2013; J. G. Jackson et al., 2014).  
 
1.2.2.3 Blood brain barrier and cerebral blood flow: Astrocytes play a 
major role in the formation and integrity of the BBB and by modulating blood flow in 
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the brain vasculature(Sofroniew, 2005). The BBB is a barrier that impedes the 
entrance of certain molecules based on polarity and size into the brain, and it is 
formed by astrocytes, capillary endothelial cells, and perivascular 
pericytes(Daneman & Prat, 2015; Meeker et al.). The capillary endothelial cells form 
tight junctions surrounded by basal lamina and pericytes, while astrocytic end feet 
cover the entirety of the capillary system. They play a role in the exchange of water 
and solutes from the capillaries to the brain. Astrocytes do this through the 
abundantly expressed aquaporin 4 (AQP4), which is a water channel in the 
astrocytic end feet(Sofroniew, 2005; Sofroniew & Vinters, 2010).  
Astrocytes were first found to have contact with blood vessels since the early 
1890s by Ramon y Cajal when investigating brain morphology(Navarrete & Araque, 
2014; W. Sun et al., 2010). Astrocyte end feet completely envelop all cerebral blood 
vessels and this interplay between end feet and cerebral vasculature is thought to be 
involved in regulating cerebral blood flow (CBF). The purpose is to match blood flow, 
and thus nutrient uptake by astrocytes, to brain metabolic demands(Macvicar & 
Newman, 2015; Stobart & Anderson, 2013). Increases in synaptic and brain activity 
increases the need for more nutrients and thus enhanced blood flow and astrocytes 
are important in matching CBF with neuronal activity. The actual changes in CBF 
through blood vessels to match neuronal activity is termed neurovascular 
coupling(Shu et al., 2016; Stobart & Anderson, 2013).   
The process of neurovascular coupling is largely mediated by astrocytic Ca2+ 
release. Through experiments with caging and uncaging Ca2+ in astrocytes, it was 
found that astrocytic Ca2+ can induce dilations and constrictions in the vasculature, 
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particularly arterioles(Bayraktar et al., 2014; Macvicar & Newman, 2015). The 
signaling pathway mediating neurovascular coupling includes the activation of 
NMDARs in neurons which increases [Ca2+]i. The increase in [Ca2+]i leads to release 
of neuronal nitric oxide which activates smooth muscle guanylate cyclase. Another 
pathway via which [Ca2+]i modulates vasodilation is through the generation of 
arachidonic acid from phospholipase A2 which is converted to prostaglandins that 
dilate vessels(Abbott et al., 2006; Cabezas et al., 2014b). Due to mGluR5 
metabotropic receptors on astrocytes, glutamate also increases astrocytic [Ca2+]i  
which then generates arachidonic acid. Then arachidonic acid is converted to 
prostaglandins for vasodilation, but also 20-HETE which can constrict blood vessels 
[132]. Vasodilation or constriction is strongly dependent on the partial oxygen levels 
in the blood (pO2) where high pO2 leads to constriction and low pO2 leads to dilation 
[131]. Vasomodulation through neurovascular coupling can also be mediated via 
astrocyte release of K+ onto blood vessels through K+ induced vasodilation. 
Vasodilation is mediated by inwardly rectifying K+ channels and Na+/K+ ATPase on 
vascular smooth muscle (Abbott et al., 2006). Both channels result in 
hyperpolarization which leads to relaxation of smooth muscle. The ability to control 
blood flow is important for many factors promoting neuronal health especially during 
metabolic dysfunction and during neurovascular damage such as stroke.   
From this section we can appreciate the critical and diverse roles that 
astrocytes play– from deciding NSC fate to maturing synapses. Many of these roles 
serve to promote and secure neuronal health and function, including the health of 
the brain. Due to the various beneficial functions that astrocytes play in neuronal 
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health it is not surprising that they can also play important protective roles during 
disease. 
 
1.2.3 Astrocytes as neuroprotectors  
 
Astrocytes play a crucial role as neuroprotectors during multiple types of 
injury. I will briefly describe the role they play in the certain injuries: glutamate 
toxicity and ischemic injury. This part of the introduction will provide a better 
understanding of how astrocytes act as potential endogenous protectors during 
cisplatin damage. It will then delve into the potential for astrocytes as protectors of 
neuronal mitochondria.   
 
1.2.3.1 Glutamate toxicity: Under basal conditions, neurons release 
glutamate into the synaptic cleft and astrocytes control the uptake of excess 
glutamate in the synaptic cleft (Benediktsson et al., 2012). This process becomes 
dysregulated after various forms of injury including physical trauma, radiation 
exposure, and neurodegenerative disorders such as Alzheimer disease. Specifically, 
during neurodegenerative disorders a prevailing idea is that damaged or dying 
neurons can release excess glutamate which then leads to excitatory cell death due 
to overstimulation of NMDARs and overproduction of ROS in neurons(Bé Langer et 
al., 2011; Bylicky et al., 2018; Kasischke, 2015b; Sofroniew & Vinters, 2010). 
Normally, astrocytes prevent glutamate excitotoxicity by taking up glutamate through 
the excitatory amino acid transporter 2 (EAAT2) and the glutamate transporter 1 
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(GLT-1)(Benediktsson et al., 2012). When such transporters are inhibited neuronal 
death from excitotoxicity is observed. Astrocytes are more resilient to excess 
glutamate than neurons. Following injury astrocytes can buffer excessive glutamate 
to prevent more neuronal death from excitotoxicity. This protective mechanism leads 
to decreased lesion size and improvement of CNS function after injury(Bylicky et al., 
2018; W. Sun et al., 2010). Severe damage, that overcomes astrocyte resiliency, 
can impact the ability of astrocytes to protect neurons from excitotoxicity(Sofroniew 
& Vinters, 2010). Moreover, astrocytes damaged by radiation have impaired 
glutamate uptake which allows neurons to uptake excessive amount of glutamate 
and lead to cell death, this also occurs during and after traumatic brain injury (TBI) 
(Mohn & Koob, 2015).  
 
1.2.3.2 Ischemic injury/Stroke: Neuroprotection by astrocytes has been well 
documented in ischemic injury and stroke models. During ischemic injury astrocytes 
will immediately undergo morphological changes such as hyperplasia and 
hypertrophy, and due to the release of cytokines from not only astrocytes but 
neurons and other glial cells such as TGF-α, Il-6 and IL-1 they will ultimately become 
activated(Bylicky et al., 2018; Pekny et al., 2014). Reactive astrocytes have 
elongated processes that surround the ischemic lesion which creates a glial scar. A 
glial scar is a physical and functional wall around the necrotic brain tissue of the 
infarct created due to proliferating astrocytes(D. Sun & Jakobs, 2012). The purpose 
of the glial scar is not completely known, and the potential benefits are still 
controversial. With that said, the scar appears to provide some benefits in that it 
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demarcates and surrounds damaged tissue which releases pro-inflammatory 
cytokines (Jensen et al., 2013; Sofroniew & Vinters, 2010; D. Sun & Jakobs, 2012). 
This inflammatory environment, if allowed to spread, could lead to further injury by 
creating a wider cascade of inflammation that might affect surrounding healthier 
tissue. The scar is thus an anti-inflammatory barrier in that it restricts the inflamed 
damaged area. Once restricted the reactive astrocytes that formed the scar can 
release anti-inflammatory cytokines to downregulate the pro-inflammatory 
milieu(Buffo et al., 2010; Z. Liu & Chopp, 2016a). Furthermore, astrocytes are more 
resilient than neurons to oxygen-glucose deprivation which can occur due to 
ischemic insult(Vanzulli & Butt, 2015). This resiliency is not only important for 
migrating to the site of the injury for glial scar formation but also in keeping 
remaining or healthier neurons alive(D. K. Ma et al., 2005b). The controversy from 
the scar comes from its inability to allow neuronal regeneration. Reactive astrocytes 
that create the barrier actively release factors that halt the movement of both neural 
stem cells and even axonal regeneration(D. Sun & Jakobs, 2012). Whether the 
inability to regenerate is in fact a neuroprotective mechanism or an overexpression 
of a protective mechanism that leads to negative effects is still being 
discussed(Pekny et al., 2014).  
Astrocytes also play an important role in maintaining the BBB during brain 
edema which occurs during cerebral stroke with consequences for the brain 
parenchyma(Sofroniew, 2005). During early insults astrocytes can mediate the 
swelling through mechanisms such as vasoconstriction (Bylicky et al., 2018; 
Cabezas et al., 2014a; Sofroniew, 2005). With that said, astrocytes can contribute to 
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this swelling due to the uptake of glutamate, K+ ions and lactate from the end feet 
around the vessels, but this usually occurs after severe injury or multiple insults 
leading to toxic edema(Sofroniew, 2005). This swelling can lead to an increase in 
intracerebral pressure and thus worsening of the ischemic injury.  
Though I have briefly touched upon a few of the most well documented 
astrocytic function and roles as neuroprotectors, it should be noted that there are 
many more roles that astrocytes play in neuronal protection and repair. A role that is 
recently being investigated and that is important to remember for this study is how 
astrocytes repair neuronal mitochondrial health and function.  
 
1.2.4 Astrocytes and neuronal mitochondrial repair 
 
Currently, it is known that astrocytes can provide defense against 
mitochondrial dysfunction in neurons through mitochondrial transfer(Gao et al., 
2019c; Hayakawa et al., 2016b). This transfer is associated with improved 
mitochondrial function of neurons and appears to be a function of astrocytes to 
repair neuronal mitochondrial. 
Mitochondrial transfer has been well understood to be an important 
mechanism by which mesenchymal stem cells (MSCs) repair damaged tissue since 
the early 2000s. Spees et al., an early observer of the effects of MSC mitochondrial 
transfer, describes that after mtDNA deletions or other defects in the 
adenocarcinomic human alveolar basal epithelial cell line, A549 ρ°, human 
mesenchymal stem cells transferred mitochondria to the damaged cells and 
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improved aerobic respiration(Hsu et al., 2016; Spees et al., 2006). Mitochondrial 
transfer from MSCs have been observed to repair damage in cardiomyopathy, 
pulmonary damage, cerebral ischemic injury and neurodegenerative disorders 
including cisplatin-induced neurotoxicity(Acquistapace et al., 2011; Babenko et al., 
2018a; D. Jiang et al., 2016; C. S. Liu et al., 2014; Vignais et al., 2017). In terms of 
cisplatin-neurotoxicity, mesenchymal stem cells will transfer mitochondria to NSCs 
and improve mitochondrial membrane potential and NSC survival(Boukelmoune et 
al., 2018b; Las & Shirihai, 2014b; C. Li et al., 2019).  
Astrocytes were first described to transfer mitochondria to neurons by Wang 
et al. Wang et al. found that astrocytes transfer mitochondria to neurons after injury 
with H2O2 and serum deprivation in vitro(Y Wang et al., 2011b). Hayakawa et al. 
published that astrocytes will transfer mitochondria to neurons following stroke to 
improve neuronal health in vitro and in vivo(Hayakawa et al., 2016a). In this study 
following oxygen-glucose deprivation in vitro, astrocytes were shown to release 
functional mitochondria to neurons. Within vivo studies using transient focal cerebral 
ischemia demonstrated that neurons take up astrocytic mitochondria as well. 
Another study by Gao et al. that further explored mitochondrial transfer from 
astrocytes to neurons used a model of Alexander’s disease, which is thought to be 
caused by dysfunctional astrocytes due to a mutation in GFAP(Gao et al., 2019a). 
The transfer was associated with increased in mitochondrial membrane potential of 
the acceptor cells, the neurons.  
Interestingly, astrocytes appear to take up mitochondria from neurons as 
shown by Davis et al(Davis et al., 2014). These authors observed that retinal 
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ganglion cell axons will transfer damaged/old mitochondria at the optic nerve head to 
astrocytes, and astrocytes will degrade the mitochondria. This is called transcellular 
degradation or transmitophagy, and it is suggested to be important for neuronal 
mitochondrial health as well as a way that astrocytes help neurons to conserve 
energy by handling an energy-heavy process such as mitophagy. Davis et al. 
suggest that this process could be possible in other areas of the brain.  
 
1.2.4.1 Role of Rhot-1/ Miro-1: The mechanisms of mitochondrial transfer 
are still being investigated but one key player that is involved or associated with 
transfer is Miro-1. Mitochondrial Rho-GTPase 1 (Miro-1) not only regulates 
intracellular mitochondrial transport and motility in both neurons, astrocytes and 
many other cell types, but also intercellular mitochondrial transfer(Joshua G. 
Jackson & Robinson, 2015; Macaskill et al., 2009; Oeding et al., 2018b; Su et al., 
2014a),(Stephen et al., 2015a). Miro-1 is a part of the larger family of Miro proteins 
that are involved in regulating mitochondrial transport along microtubules by linking 
mitochondria to kinesin and dynein motors. Lopez-Domenech et al. observed, using 
a double knockdown of Miro1/2 in mice, that Miro is critical for recruiting and 
stabilizing mitochondrial myosin, Myo19, an actin-based mitochondrial motor, on 
actin thus allowing the transport of mitochondria. Miro1/2 heterozygous knockdown 
in mice led to aberrant transport and positioning of mitochondria during cell division, 
presumably since Myo19 is not stabilized on actin for mitochondrial 
movement(López‐Doménech et al., 2018). Miro-1 also interacts with the motor 
proteins TRAK1 and TRAK2(Schwarz, 2013a). With Miro-1 knockdown TRAK1 and 
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TRAK 2 can still localize to the outer mitochondrial membrane and drive anterograde 
mitochondrial motility but, TRAK2 mediated- retrograde motility was impeded with 
Miro-1 knockdown(Oeding et al., 2018a).  
Within astrocytes, Miro-1 is important for remodeling the movement of 
mitochondria in response to areas of high neuronal activity such as the tripartite 
synaptic cleft. Stephen et al. explored how Miro-1 also regulates mitochondrial 
remodeling in astrocytes based on neuronal activity using rat organotypic 
hippocampal slices(Stephen et al., 2015b). Furthermore, Stephen et al. observed 
that enhancing neuroactivity, mediated by elevations of intracellular Ca2+, induces 
mitochondrial remodeling in astrocytes. This means that Miro-1 regulates not only 
the mitochondrial remodeling but also movement of astrocytic mitochondria to areas 
of high neuronal activity through the Ca2+ sensing EF-hand domains of Miro-1. Miro-
1 dependent mitochondrial positioning regulates the levels of intracellular Ca2+ in 
astrocytes as well as neurons which could suggest that astrocytes play a role in Ca2+ 
propagation and thus neuronal function(Stephen et al., 2015a; Su et al., 2014a). 
Moreover, Nemani et al. reported that the Ca2+ sensing activity of Miro-1 is also 
important to enable mitochondrial shape transition so Miro-1 is also involved in 
altering mitochondrial shape(Nemani et al., 2018). This is important in terms of 
astrocytic mitochondrial transfer in response to neuronal damage because it could 
be the case that Miro-1 is not only involved in the movement of mitochondria but 
also the shaping of mitochondria during transfer. Moreover, in terms of neurons 
transferring low quality mitochondria to astrocytes for transmitophagy, Miro-1 may be 
involved in the degradation of damaged/old neuronal mitochondria in astrocytes. 
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In terms of mitochondrial transfer, Miro-1 has been observed to be involved in 
the mitochondrial transfer mechanisms of mesenchymal stem cells. Babenko et al. 
found that overexpressing Miro-1 in MSCs led to improved recovery after injury in 
ischemic stroke models possibly through MSC-derived mitochondrial transfer to 
neuronal stem cells(Babenko et al., 2018a). Boukelmoune et al. also found that 
overexpressing Miro-1 in MSCs led to increased mitochondrial transfer to NSCs as 
well resulting in greater improvement in NSC health in comparison to 
WT(Boukelmoune et al., 2018b). Whether Miro-1 is involved in astrocytic 
mitochondrial transfer to neurons is still unknown.  
 
1.3 Summary 
 From this introduction I have provided background important for these points 
of the study: (1) cisplatin is an efficient platinum-based chemotherapy drug that 
induces severe neuronal dysfunction in the CNS as well as other systems, (2) a 
predominant mechanism of cisplatin neurotoxicity is confined to mitochondrial 
damage, (3) mitochondria are sensitive to cisplatin due to lack of repair mechanisms 
in mtDNA in comparison to nuclear DNA, (4) despite the insult by cisplatin neurons 
do not die, indicating a potential endogenous repair mechanism, (5) astrocytes could 
protect neuronal mitochondrial health in the presence of cisplatin through 
mitochondrial transfer. This dissertation will now explore how astrocytic 
mitochondrial transfer may play a role in protecting and promoting neurons and 
potentially neural stem cells in the presence of cisplatin neurotoxicity.
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Chapter 2: Materials and Methods 
 
2.1 Culture of rat cortical neurons, rat cortical astrocytes, mouse cortical 
neurons and mouse NSCs 
 
Timed-pregnant Long Evans rats (Charles River, Wilmington, MA, USA) were 
sacrificed and E18 fetuses of both sexes were collected in accordance with 
Institutional Animal Care and Use Committee (IACUC)-approved protocols. 
Cortices were dissected and incubated in 10 ml of dissociation media (81.8 
mM Na2So4, 30 mM K2SO4, 5.8 mM MgCl2, 0.25 mM CaCl2, 1 mM Hepes, 20 mM 
glucose, 0.0001% Phenol Red, 0.16 mM NaOH pH=7.4) that contained 10 U/mL 
papain and 5 mg of L-cysteine in total (Worthington, Lakewood, NJ, USA) for 10 
minutes at 37 ᵒC, followed by incubation with 150 mg of trypsin inhibitor (Millipore-
Sigma, St. Louis, MO) in 10 ml of dissociation media for 10 minutes at 37 ᵒC. The 
cortical tissue was mechanically dissociation in Opti-mem (GIBCO, Carlsbad, CA, 
USA) with 2.5 M Glucose (GIBCO). Cells were cultured on plates coated with 0.05 
mg/ml poly-D-lysine (PDL; Millipore-Sigma) in neurobasal medium (NBM) with 
100 U/mL penicillin and 1x B-27 supplement (Invitrogen Carlsbad, CA) at 37 °C and 
5% CO2. Neuronal cultures were maintained in NBM with B-27 supplement and 
media was replaced every 3 days. Cortical astrocytes were grown in DMEM/F12 
medium supplemented with 10% fetal bovine serum and 5% of 10,000 units/ ml of 
penicillin and 10,0000 µg/ml of streptomycin (GIBCO) at 5% CO2 and 37 °C. 
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We cultured mouse cortical NSCs using the approach of Boukelmoune et al. 
which they describe below(Boukelmoune et al., 2018d). Mouse cortical NSCs (R&D 
Systems, Minneapolis, MN, USA) were cultured as a monolayer in low-glucose 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12, supplemented with 100 U/mL 
penicillin and N-2 plus supplement (R&D Systems). Fibroblast growth factor basic 
and epidermal growth factor (both 20 ng/mL; R&D Systems) were added to the 
cultures daily. NSCs were cultured on surfaces coated with poly-L-ornithine (Sigma-
Aldrich, St. Louis, MO, USA) and bovine fibronectin (R&D Systems) and detached 
using Accutase (Innovative Cell Technologies, San Diego, CA, USA). The NSCs 
used for experiments were 52% Nestin+, 17% GFAP+, 16% Nestin/GFAP double-
positive, 92% DCX+, 94% Sox2+ and 5% βIII-Tubulin+ as characterized by 
Boukelmoune et al ((Boukelmoune et al., 2018c)).  
For mouse cortical astrocytes, both sexes of p1-p4 mice pups were sacrificed 
in accordance with IACUC-approved protocols. Cortices were removed and 
incubated in HBSS (total volume 22.5 ml; Sigma). 2.5% Trypsin (Sigma) was added 
and the Trypsin-HBSS solution was incubated at 37 °C for 30 minutes. The solution 
was then vortexed for 5 min at 300 x g to pellet cortex pieces. The Trypsin-HBSS 
solution was removed and fresh DMEM/F12 (Sigma) media supplemented with 10% 
fetal bovine serum and 5% of 10,000 units/ ml of penicillin and 10,0000 µg/ml of 
streptomycin (GIBCO) was added before dissociating the cortical tissue into single 
cells. The cells were plated on T75 flask (Thermo Fischer) prepared with 0.05% 
PDL. Two days after plating the media was changed before the flasks were shaken 
with an orbital shaker (Thermo Scientific) at 180 rpm for 30 minutes. The media was 
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changed, and the shaking continued at 240 rpm for 6 hours where the media was 
changed again.  
Cortical rat neuronal cells were used for experiments after 12-15 days of 
culturing in vitro (DIV). To confirm neuronal enrichment, cells were fixed with 4% 
paraformaldehyde in PBS, treated with 0.25% Triton X-100, blocked in 2% BSA in 
PBS and stained with anti-Map2 antibody (1:2000); Sigma-Aldrich); anti-GFAP 
(1:200, Acris, Rockville, MD) and anti-Olig2 (1:400, Abcam, Cambridge, UK) 
antibody. On DIV12 > 98% of cells were Map2+ and Olig2 and GFAP-negative. 
Astrocytes were used until the third passage (for both rat and mouse) and were 
>99% GFAP+.   
 
2.2 Astrocyte transfections 
 
Astrocytes were plated in a 6-well plate at 1.5 x 105 cells/well 24 hours before 
transfection. For labeling mitochondria, astrocytes were transfected with 2 µg of 
pLYS1-FLAG-MitoGFP-HA (Addgene plasmid # 50057) which contains the pore-
forming subunit of the mitochondrial calcium uniporter coupled to GFP or a mito-
mCherry construct generated by subcloning the targeting sequence of the pLYS1-
FLAG-MitoGFP-HA plasmid into the mcherry2-N1 vector (Addgene plasmid # 
54517).  For Miro-1 knockdown, 5nmol of Rho-1 siRNA (Qiagen, Germany 
#SI01401743) was diluted in Rnase-free water (provided in kit) to make a 20 µM 
stock, and AllStars Negative Control Scrambled siRNA (Qiagen #SI03650318) was 
performed similarly to make a 20 µM stock instructions provided. Astrocytes were 
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transfected with 80 nM of Rho-1 siRNA from a 20 µM stock (Qiagen, Germany 
#SI01401743) or 80 nM AllStars Negative Control Scrambled siRNA from a 20 µM 
stock (Qiagen #SI03650318). All transfections were performed using the Astrocyte 
Transfection kit (Altogen Biosystems, Las Vegas, NV, USA) according to 
manufacturer’s instructions. Miro-1 knockdown was confirmed by Western blot with 
anti-Rho1 antibody (Novus Biologicals, Centennial, CO, USA) with GAPDH as 
control (Abcam) followed detection of bands with enhanced chemoluminescence 
(GE Healthcare Bio-Sciences, Pittsburgh, PA). Blots were captured in the LAS 
system using Image Quant software (GE Healthcare Bio-Sciences) for quantification 
of bands. Mouse cortical astrocytes were tranduced with a lentiviral construct 
consisting of a DsRed plasmid targeted to the PDHA1 mitochondrial protein known 
as pCD510-PDHA1-DSred. This plasmid was a gift from Dr. R. Jacamo (Department 
of Leukemia, University of Texas MD Anderson Cancer Center). We are unable to 
provide further information about this product including transduction methods due to 
the owner’s restrictions.  
 
2.3 Analysis of neuronal survival 
 
Neurons were plated in 96 well plates coated with 0.05 mg/ml PDL at 5 x 104 
neurons/well.  Viability after exposure to cisplatin (Teva, Petah Tikva, Israel) was 
quantified using the colorimetric cell viability reagent WST-1 (Millipore-Sigma, 
#11644807001).  To assess the effect of astrocytes on neuronal survival, separate 
cultures of neurons (1.5 x 105 cells/well in a 6-well plate) and astrocytes (5 x 104 
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/well in a 6-well plate) were treated with cisplatin for 24 h. Neurons were then 
labeled with 20 μM CellTracker Blue (CTB; Invitrogen) for 45 min at 37 °C, and 
washed in serum-free media. Astrocytes (5 x 104 cells/well) were added to the 
neuronal culture and survival of CTB+ neurons were quantified 17 hours later using 
a Countess II FL automated cell counter (Invitrogen).  
  
2.4 Analysis of mitochondrial membrane potential and mitochondrial transfer 
 
Neurons were plated at 1.5 x 105 cells/well in a 6-well plate, treated with 
cisplatin for 24 h, and labeled with 20 µM CellTracker Green (Thermo Fisher). 
Astrocytes (5 x 104 cells/well) were added and co-cultured with the neurons for 17 h. 
The co-cultures were stained with tetramethylrhodamine methyl ester (TMRM, 
Invitrogen; 250 nM) for 45 min at 37 °C, or Mitotracker (50 nM, Thermo Fisher, 
Waltham, MA, USA) for 30 min at 37 °C. As a positive control, neurons were treated 
with 10 μM carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP, Sigma-
Aldrich), a mitochondrial uncoupler, for 15 min. Cells were collected and TMRM 
fluorescence intensity of the cell tracker green positive cells was quantified using an 
Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA USA). For confocal 
microscopy, neurons were plated in cell culture imaging dishes (ibidi, Fitchburg, WI, 
USA), treated with cisplatin, stained with CTB and cultured with or without mito-GFP 
and cell tracker deep red-labeled astrocytes for 17 h followed by staining with TMRM 
or Mitotracker. The TMRM was used in sub-quench mode as described previously 
(Rego et al., 2001). 
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For analysis of mitochondrial transfer, neurons exposed to cisplatin or vehicle 
were labeled with 20 µM CTB (Thermo Fisher) prior to co-culture with astrocytes. 
Astrocytes were transfected with either mito-GFP or mito-mCherry prior to exposure 
to cisplatin followed by labeling with 20 µM Celltracker DeepRed (Thermo Fisher) 
and co-culture with neurons. Neurons containing an area positive for the mito-GFP 
or mito-mCherry signal that was larger than 8 pixels were scored as containing 
astrocyte-derived mitochondria. The co-cultures were imaged on an SPE Leica 
Confocal Microscope (Leica Microsystems, Buffalo Grove, IL, USA) with a 63 X or 
40 X objective and images were analyzed with LAS X software. 
 
2.5 Analysis of mitochondrial bioenergetics 
 
To assess mitochondrial bioenergetics, astrocytes (5 x 104 cells/well) were 
plated in a Seahorse XFe 24 microplate (Seahorse Biosciences/Agilent 
Technologies, Santa Clara, CA, USA) coated with 0.05 mg/ml PDL and treated with 
1 μM cisplatin or vehicle for 24 h. Cells were washed and incubated for 1 h at 37 °C 
in XF base media (Seahorse Biosciences) supplemented with 11 mM glucose 
(Sigma-Aldrich), 2 mM glutamine (Sigma Aldrich), and 1 mM pyruvate (Sigma-
Aldrich), 2 mM Oligomycin (Sigma-Alrich), 4 mM FCCP, and rotenone/antimycin A 
(Sigma-Aldrich, 2 mM each) were used with a 3-time repeat of a 2-min mix, 3-min 
wait, and 2-min measure assay cycle. Oxygen consumption rates were normalized 
to the total protein content of each well. Basal respiration, maximal respiratory 
capacity, and spare respiratory capacity were determined as described previously 
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((Boukelmoune et al., 2018c)). To analyze the data, we followed the 
recommendations provided by Agilent(Report Generator User Guide Agilent 
Seahorse XF Cell Mito Stress Test, n.d.). 
 
2.6 Co-culture of astrocytes and NSCs  
NSCs (3.5 x 104) were plated on ibid-low imaging dishes (ibidi, Fitchburg, WI, 
USA). Two days after plating, NSCs and astrocytes were treated with 1 µM cisplatin 
(Teva, Petah Tikva, Israel) for 8 h. After 8 h NSCs were stained with 20 µM 
CellTracker Blue fluorescent probe (CTB; Invitrogen, Carlsbad, CA) for 45 min at 
37°C, and washed twice with serum-free media.  Astrocytes were stained with 20 µM 
Celltracker Deep Red, trypsinized and added to NSCs (3.5 x 104) for culture for 17 h. 
Cultures were then prepared for live cell imaging in Live Cell Imaging Solution 
(Invitrogen). 
 
2.7 Calcium imaging 
 
Functional Ca2+ imaging on cortical neurons was performed as described 
previously ((Shepherd et al., 2018)). 12 mm circular glass coverslips containing cells 
were incubated at room temperature for 20 min with the Ca2+-sensitive dye Fura-2-
AM (Invitrogen, 2 μM), dissolved in standard extracellular HEPES-buffered HBSS 
(known hereafter as extracellular imaging buffer) containing the following (in mM): 
140 NaCl, 5 KCl, 1.3 CaCl2, 0.4 MgSO4, 0.5 MgCl2, 0.4 KH2PO4, 0.6 NaHPO4, 3 
NaHCO3, 10 glucose, and 10 HEPES adjusted to pH 7.4 with NaOH and 310 mOsm 
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with sucrose. The coverslip was placed in the recording chamber (ALA scientific 
Instruments, Farmingdale, NY, USA) mounted on the stage of an inverted Nikon Ti2 
microscope and continuously superfused for 5 min at room temperature with 
extracellular imaging buffer. Fura-2 fluorescence was alternately excited at 340 and 
380 nm (12 nm band-pass, 50ms exposure) at 1 Hz using a Lambda LS Xenon lamp 
(Sutter Instruments, Novato, CA, USA) and a 10x/NA 0.5 objective or 40x/NA 0.6. 
The CFI Super Fluor 10X was used to measure the ratio of Fura-2 fluorescence. 
Emitted fluorescence was collected at 510 nm using a sCMOS pico.edge camera for 
the entire experimental duration, including the first 5 min wash duration, and the ratio 
of fluorescence (F340:F380) was calculated. The shift in the ratio of Fura-2 
fluorescence between excitation at 340 nm versus 380 nm is used as a readout of 
changes in intracellular calcium concentration [Ca2+i]. Baseline recording of 
F340:F380 ratio without stimulus was completed to obtain an indication of resting 
[Ca2+i]. Neurons were stimulated with 20 mM of KCl in the extracellular imaging 
buffer with continuous superfusion at room temperature. Imaging was analyzed with 
the NIS Elements software. To identify neurons that did or did not receive astrocytic 
mitochondria, the Nikon inverted Ti2 microscope with associated A1Rsi-HD confocal 
system and NIS Elements software was used with the CFI S Plan Fluor ELWD 40XC 
objective. A single exposure at 576 nm excitation was used to quantify fluorescence 
within neurons before beginning measurement of F340:F380 ratio. 
 




Data are presented as mean ± SEM of at least 3 independent experiments 
performed in duplicate or triplicate. For survival analysis and mitochondrial 
membrane potential analysis, data were normalized to the control of each 
experiment and replicates were averaged. We used One-way or Two-way analysis 
of variance (ANOVA) with or without repeated measure followed by Tukey’s 
correction for multiple comparisons or Sidak’s correction for multiple comparisons 
according to experimental set up. For mitochondrial transfer analysis, the 
percentage of neurons that received mitochondria was calculate for each group. We 
used Student’s t-test or Two-way analysis of variance (ANOVA) without repeated 
measures followed by Tukey’s correction for multiple comparisons. For calcium 
imaging, the ratio of fluorescence (F340:F380) was calculated and the ratios at 
baseline were subtracted from the maximum peak values upon KCl stimulus to 
calculate change in [Ca2+i].  To calculate Ca2+ clearance, F340:F380 ratios were 
converted to a 0-1 scale with 1 being the maximum value in response to 20 mM KCl. 
Then, we quantified the time to return to 20% of baseline by counting the values 
from 1 (maximum peak) to 20% of the baseline value for each neuron. All analyses 









Chapter 3: Astrocytes rescue neuronal health after cisplatin treatment through 
mitochondrial transfer. 
 
This chapter is based upon English, K., Shepherd, A., Uzor, N. et al. 
Astrocytes rescue neuronal health after cisplatin treatment through mitochondrial 
transfer. Acta Neuropathol. Commun 8, 36 (2020). https://doi.org/10.1186/s40478-
020-00897-7(English et al., 2020).  As per the rights and permissions of this journal: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. No changes were 
made to this article.  
This chapter reports on astrocytic mitochondrial transfer to neurons in the 
presence of cisplatin and improvement of neuronal health including mitochondrial 
function. As has been explained previously cisplatin neurotoxicity leads to heavy 
mitochondrial damage but this does not necessarily lead to neuronal death as shown 
in in vivo models. Furthermore, though patients suffer from cognitive dysfunction 
with cisplatin-based chemotherapy treatments they do recover in time. This may 
indicate a potential endogenous mechanism that not only prevents neuronal death 
but repair mechanism for neurons. As mitochondria play an important role in 
neurons and are preferentially targeted by cisplatin, we wanted to investigate if there 
were endogenous protective mechanisms to prevent or reverse neuronal 
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mitochondrial damage. We investigated astrocytes because of their well-established 
protective roles in neurological disorders such as stroke. Astrocytes are known to be 
resilient to cisplatin in comparison to neurons ((Dietrich et al., 2006b)).  
With this study we explore astrocytes as neuroprotectors during cisplatin- 
induced neuronal damage with a specific focus on the transfer of mitochondria from 
astrocytes to neurons. This study investigates the role of astrocytic mitochondrial 
transfer with respect to neuronal mitochondrial membrane potential, neuronal Ca2+ 
dynamics, and neuronal survival. We also explored the role of Miro-1 in astrocytic 
mitochondrial transfer to neurons after cisplatin treatment.   
 
Results 
3.1 Astrocytes improve neuronal survival after cisplatin treatment. 
To examine the effect of cisplatin on neuron and astrocyte survival, we 
treated separate cultures of primary cortical neurons and astrocytes with cisplatin for 
24 h and measured survival using the WST assay. Cisplatin dose-dependently 
reduced neuronal survival as assessed immediately after removal of cisplatin (Figure 
1A) or 17 hours later (Figure 1B). Astrocytes were shown to be resistant to cisplatin 
since only the highest dose (4 µM) resulted in a modest reduction in astrocyte 
survival (Figure 1C and D). For all further experiments we used cisplatin at a dose of 
1 µM. Exposure of astrocytes to 1 µM cisplatin did not induce detectable changes in 
astrocytic mitochondrial respiration; basal respiration, spare respiratory capacity and 




To test the hypothesis that astrocytes improve the survival of neurons treated 
with cisplatin, primary cortical neurons and astrocytes were cultured separately in 
the presence or absence of 1 µM cisplatin for 24 h. Next cisplatin was removed, 
neurons were labeled with celltracker blue (CTB), and co-cultured with astrocytes for 
an additional 17 h. Co-culture with astrocytes significantly improved survival of 
cisplatin-treated neurons. Astrocytes did not affect survival of neurons under control 








           
                
                              
 






























































































































































Figure 1.1: Astrocytes improve neuronal survival after cisplatin treatment.  
A-D. Survival of neurons (A, B) and astrocytes (C, D) after exposure to cisplatin. 
Primary cultures of cortical neurons (12 days in vitro) or cortical astrocytes were 
treated with increasing doses of cisplatin or vehicle for 24 h, then the cisplatin was 
removed and replaced with media. Survival was measured using a WST-1 assay: 
(A, C) at the end of the 24 h culture period or (B, D) 17 h after removal of cisplatin. 
Data was normalized to survival in the absence of cisplatin and analyzed using one-
way ANOVA followed by Dunnett’s multiple comparisons test (*p<0.05, **p<0.01, 
***p<0.001). E. Astrocytes were treated with 1 µM cisplatin for 24 h followed by 17 h 
of culture without cisplatin. Oxygen consumption rates (OCR) were analyzed using 
Seahorse XFe 24 Analyzer and normalized to protein content. F. Neurons and 
astrocytes were treated with cisplatin or control medium for 24 h. Cisplatin was 
removed, neurons were labeled with Celltracker Blue (CTB) and cultured for another 
17 h with or without astrocytes, and the number of surviving neurons was counted. 
Data are normalized to control and represents the mean ± SEM of 3 independent 
experiments performed in duplicate. Two-way ANOVA:  cisplatin x astrocyte 








3.2 Astrocytes improve mitochondrial membrane potential of neurons 
damaged by cisplatin.  
To assess the effect of cisplatin on neuronal mitochondrial integrity, we 
quantified the mitochondrial membrane potential by labeling the cells with 
tetramethylrhodamine (TMRM) and assessed fluorescence intensity by flow 
cytometry. Figure 2A clearly shows that cisplatin depolarized the neuronal 
mitochondrial membrane potential as indicated by a reduction in TMRM 
fluorescence intensity. The cisplatin-induced reduction in TMRM fluorescence 
intensity was not associated with changes in neuronal mitochondrial content as 
determined by labeling mitochondria with the membrane potential-independent dye 
Mitotracker (Figure 2B). Together these findings indicate that cisplatin reduces 
neuronal mitochondrial membrane potential without leading to an actual loss of 
mitochondria under the conditions tested. Co-culture with astrocytes restored the 
mitochondrial membrane potential of neurons cultured with cisplatin (Figure 2A). 
Confocal microscopy confirmed that cisplatin reduces TMRM staining in somata and 
dendrites of neurons and that co-culture with astrocytes restored TMRM staining 
(Figure 2C and Supplemental Figure). The increase in TMRM fluorescence intensity 
of cisplatin-treated neurons in response to astrocytes was associated with an 
increase in mitotracker fluorescence intensity in neuronal cells (Figure 2B), 







                  
 
































































Figure 1. 2:  Astrocytes improve mitochondrial membrane potential of neurons 
damaged by cisplatin.  
After treating neurons and astrocytes separately with and without cisplatin for 24 h, 
neurons were labeled with Celltracker Green (CTG) and co-cultured with astrocytes 
for 17 h. Cells were labeled with TMRM (A) to assess mitochondrial membrane 
potential or with Mitotracker (B) to quantify mitochondrial content by FACS analysis. 
Fluorescence intensity was normalized to fluorescence intensity in control CTG-
positive neurons for each experiment and data represents the mean ±SEM of 3 
independent experiments performed in duplicate. Two-way ANOVA TMRM: cisplatin 
x astrocyte interaction: *p< 0.05; Tukey’s post-hoc test: **p<0.01.  Mitotracker: 
cisplatin x astrocyte interaction: *p< 0.05; Tukey post-test: *p<0.05, ***p<0.001. (C). 
Representative confocal images of the TMRM signal (red) with neurons labeled with 













3.3 Astrocytes transfer mitochondria to neurons damaged by cisplatin. 
Next, we tested the hypothesis that astrocytes transfer mitochondria to 
neurons damaged by cisplatin. We labeled astrocyte mitochondria with mCherry 
coupled to a mitochondrial localization sequence (mito-mCherry). Neurons and 
astrocytes were treated separately with cisplatin or control medium for 24 h; neurons 
were labeled with Celltracker Blue, and co-cultured with Celltracker Deep Red-
labeled astrocytes for an additional 17 h. Confocal fluorescence analysis revealed 
that cisplatin-treated neurons contained astrocyte-derived mCherry+ mitochondria. 
Only a few astrocyte-derived mitochondria were present in untreated control neurons 
co-cultured with astrocytes (Figure 3A-C). These findings indicate that astrocytes 
transfer mitochondria to neurons damaged by cisplatin. Quantitative assessment of 
mitochondrial transfer showed that cisplatin induced an approximately 3-fold 
increase in the percentage of neurons that had received mitochondria from 
astrocytes (Figure 3D). 3D reconstruction and orthogonal section analysis confirmed 
that the mito-mCherry+ mitochondria are localized inside the neurons and were 









































Figure 1.3: Astrocytes transfer mitochondria to neurons damaged by cisplatin. 
 (A). Representative confocal image of untreated neurons co-cultured for 17 h with 
astrocytes in which mitochondria were labeled with a plasmid which contains the 
pore-forming subunit of the mitochondrial calcium uniporter coupled to mCherry 
(mito-mCherry).  (B-C). Representative confocal images of co-cultures of cisplatin-
treated neurons labeled with CTB and cisplatin-treated astrocytes in which 
mitochondria were labeled with mCherry. Middle panel: larger magnification of the 
boxed area in B/C. (E-F). 3-D reconstruction and orthogonal slicing showing that the 
astrocyte-derived mCherry-positive mitochondria (identified by arrows in the middle 
panel) are present within the neurons. Scale bar: 25 µm. (D). Quantification of 
neurons in co-cultures containing mCherry+ astrocyte-derived mitochondria. Paired 
Student’s t-test **p<0.01.  Data represents the mean ±SEM of 3 independent 













3.4 Role of Miro-1 in mitochondrial transfer from astrocytes to neurons. 
We next assessed the contribution of Miro-1, a Rho-GTPase mitochondrial 
adaptor protein, to mitochondrial transfer from astrocytes to damaged neurons. 
Astrocytes were transfected with short interfering RNA (siRNA) to knock down Miro-
1 (astrocytesMiro-1 siRNA) and mitochondria in astrocytes were labeled with mito-GFP. 
Miro-1 siRNA decreased astrocytic Miro-1 by approximately ~50% (Figure 4 inset). 
Neurons were treated with cisplatin and co-cultured with astrocytesMiro-1 siRNA or 
astrocytesScr siRNA as a control and mitochondrial transfer was quantified. The results 
in Figure 4 show that knockdown of Miro-1 in astrocytes decreased mitochondrial 
transfer to neurons in comparison to astrocytes treated with control scrambled 
siRNA (Figure 4). These findings indicate that Miro-1 plays a key role in the transfer 







Figure 1.4: Role of Miro-1 in mitochondrial transfer from astrocytes to 
neurons. 
Astrocytes were transfected with mito-GFP and Miro-1 siRNA or control 
scrambled (Scr) siRNA cultured with or without cisplatin 24 hours and co-cultured for 
17 hours with neurons treated with or without cisplatin. Using confocal microscopy 
the percentage of neurons containing GFP was quantified. Data represents the 
mean ±SEM of 3 independent experiments performed in duplicate. Inset: Western 
blot to confirm knockdown of Miro-1 in astrocytes after transfecting with mito-GFP, 
Scr and Miro-1 siRNA. The percentage of knockdown was normalized to the control 
and quantified. Two-way ANOVA cisplatin x transfected astrocyte interaction: 










































3.5 Effects of cisplatin and astrocytes on neuronal calcium dynamics. 
We next asked whether cisplatin alters neuronal Ca2+ levels and whether co-
culture with astrocytes affects cisplatin-induced changes in neuronal calcium 
dynamics. Resting [Ca2+i] levels, as measured using the calcium indicator Fura-2, 
were significantly higher in cisplatin-treated neurons than in control neurons (Figure 
5A and B). Co-culture with astrocytes normalized resting [Ca2+i] levels in cisplatin-
treated neurons (Figure 5A and B). The increase in neuronal [Ca2+i] level in 
response to 20 mM KCl was smaller in cisplatin-treated than in control neurons and 
was normalized by co-culture with astrocytes, indicating that astrocytes normalize 
calcium dynamics in neurons treated with cisplatin. (Figure 5C and D).  
Treatment of neurons with cisplatin increased the time to reach 80% 
clearance of [Ca2+i] after exposure to 20 mM KCl (Figure 5E and F), even though 
maximal calcium levels were significantly lower in cisplatin-treated neurons (Figure 
5A and B).  These findings indicate Ca2+ clearance is impaired in cisplatin-treated 
neurons. Co-culture with astrocytes increased the rate of calcium clearance in 
cisplatin-treated neurons to a level that was even higher than that the clearance in 
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Figure 1.5: Effects of cisplatin and astrocytes on neuronal calcium dynamics. 
Neurons were treated with cisplatin followed by co-culture with astrocytes and 
calcium dynamics were monitored with Fura-2.  (A, B). Resting ratio of 340:380 
Fura-2 fluorescence intensity (F340:F380) as an indicator of intracellular levels of 
Ca2+ of neurons treated with or without cisplatin followed by co-culture with or 
without astrocytes. (A). Mean traces and SEM of the F340:F380 ratio of Fura-2 at 
baseline during first 50 seconds of recording. (B). Mean F340:F380 ratio during 50 
seconds of recording for each neuron at rest. Data represents the mean ±SEM of 
>90 neurons total per group collected in 3 independent experiments. One-way 
ANOVA, followed by Tukey’s post-hoc test: (*p<0.05, ***p<0.001, ****p<0.0001). (C). 
Mean traces and SEM of the increase in F340:F380 ratio of Fura-2 of neurons 
responding to stimulation with 20 mM KCl. The threshold changes in Fura-2 
F340:F380 ratio to be considered a response to 20 mM KCl was set at an increase 
of >5 x standard deviations above baseline average. This excluded 9% of neurons in 
the control group, 23% of neurons in the cisplatin group and 11% of neurons in the 
cisplatin + astrocyte group. Data represents the mean ±SEM of 3 independent 
experiments with > 70 neurons for each group. (D). Mean change in F340:F380ratio 
in response to stimulation of neurons with 20mM KCl. The increase in Fura-2 ratio in 
response to 20 mM KCl was calculated for each neuron.  Data represent the mean ± 
SEM of n>90 neurons for each group collected in 3 independent experiments. One-
way ANOVA, followed by Tukey’s post-hoc test: (**p<0.01, ***p<0.001, 
****p<0.0001). (E)  Normalized KCl responses show a delayed decay of Ca2+ influx 
in cisplatin-treated neurons vs. control and cisplatin + astrocytes groups. (F). 
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Quantification of latency to return to 20% of maximal Ca2+ (dotted line).  Data 
represents the mean ±SEM of 3 independent experiments with > 70 neurons for 






















3.6 Mitochondrial transfer underlies the beneficial effects of astrocytes on 
calcium dynamics in damaged neurons 
To address the question of whether transfer of mitochondria from astrocytes 
to neurons contributes to the improved neuronal Ca2+ dynamics, we compared 
calcium responses to 20 mM KCl of neurons that did or did not contain mCherry+ 
mitochondria on the same coverslip. As shown in Figure 6A, neurons that contained 
astrocyte-derived mitochondria showed a larger increase in 20 mM KCl evoked 
[Ca2+i] in comparison to neurons in the same culture that did not receive astrocytic 
mitochondria (Figure 6A). This finding indicates that transfer of mitochondria from 
astrocytes to neurons plays a substantial role in restoring the KCl evoked [Ca2+i] 
increase in neurons damaged by cisplatin. 
To further address the contribution of mitochondrial transfer to the 
normalization of calcium dynamics in neurons in response to co-culture with 
astrocytes, we assessed the effect of astrocytic Miro-1 knockdown. The results in 
Figure 6B and C show that basal calcium levels were lower in cisplatin-damaged 
neurons co-cultured with control astrocytesScr siRNA  as compared to astrocytesMiro-1 
siRNA . This indicates that knockdown of Miro-1 in astrocytes prevented the 
normalization of baseline calcium levels in cisplatin-treated neurons (Figure 6B and 
C).  Similarly, co-culture of cisplatin-treated neurons with astrocytesMiro-1 siRNA failed 
to normalize the 20 mM KCl evoked [Ca2+i] that was observed in the presence of 
control astrocytesScr siRNA  (Figure 6D and E). This indicates that the restorative 
effects of astrocytes on calcium dynamics in cisplatin-treated neurons are abrogated 


















Figure 1.6: Mitochondrial transfer underlies the beneficial effects of astrocytes 
on calcium dynamics in neurons damaged by cisplatin.  
(A). Neurons were treated with and without cisplatin for 24 h and co-cultured 
with astrocytes transfected with mito-mCherry (labeled mCh) for 17 h. The calcium 
response to 20 mM KCl was compared in cisplatin-treated neurons cultured without 
astrocytes (black bar), or with astrocytes separated into mCherry negative neurons 
(orange bar; do not contain astrocytic mitochondria) and mCherry positive neurons 
(blue bar; contain astrocyte-derived mitochondria). The mean increase in the 
F340:F380 ratio of Fura-2 fluorescence in response to 20 mM KCl was calculated as 
in figure 5. Data represents the mean ±SEM of 3 independent experiments with 
n=24 neurons in total. One-way ANOVA, followed by Tukey’s post-hoc test: 
(**p<0.01, ***p<0.0001).  (B). Resting F340:F380 ratio of Fura-2 of neurons treated 
with cisplatin followed by co-culture with astrocytes transfected with mito-GFP and 
scr siRNA or Miro-1 siRNA. (C). Mean F340:F380 ratio was calculated for each 
neuron for first 50 seconds and data represents the mean ±SEM of 3 independent 
experiments with n>80 neurons for each group. Two-way ANOVA: cisplatin x 
transfected astrocyte interaction: ***p<0.001 followed by Tukey’s post-hoc test: 
(***p<0.001, ****p<0.0001). (D). Mean traces and SEM of the F340:F380 ratio in 
response to 20 mM KCl stimulus in neurons treated with and without cisplatin and 
co-cultured with astrocytes transfected with scrambled (Scr) or Miro-1 siRNA. The 
mean F340:F380 ratio KCl responses were normalized to baseline. (E). The change 
in F340:F380 ratio between baseline and maximum peak value from the 20 mM KCl 
stimulus was calculated which correlated with [Ca2+]i increase in neurons. Mean 
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increase in F340:F380 ratio ratio was calculated for each neuron for 3 sec before 20 
mM KCl and subtracted from mean F340:F380 ratio at the maximum response to 20 
mM KCl.  Data represents the mean ±SEM of 3 independent experiments with n > 
80 neurons for each group. Two-way ANOVA: cisplatin x transfected astrocyte 





















3.7 Summary  
This study demonstrates that: 1) Astrocytes rescue survival and function of 
neurons damaged by cisplatin by donating their mitochondria to cortical neurons. 2) 
Mechanistically, we show that cisplatin depolarizes neuronal mitochondrial 
membrane potential without decreasing neuronal mitochondrial content. Astrocytes 
restore neuronal mitochondrial membrane potential leading to an increase in 
mitochondrial content. 3) Miro-1 siRNA decreases mitochondrial transfer from 
astrocytes to neurons indicating that Miro-1 is involved in astrocytic mitochondrial 
transfer. 4) Cisplatin increased resting [Ca2+i] levels in neurons and impaired 
neuronal calcium clearance. Astrocytes normalized neuronal resting [Ca2+i] levels 
and improved neuronal calcium clearance. 5) To investigate that the transfer of 
mitochondria is crucial for the rescue of neuronal function, we show here that those 
neurons that contained astrocyte-derived mitochondria had improved response to 20 
mM KCl in comparison to neurons that did not contain astrocyte-derived 
mitochondria. Astrocytes transfected with Miro-1 siRNA, which decreases 
mitochondrial transfer from astrocytes to neurons, failed to prevent the normalization 
of baseline calcium levels and response to 20 mM KCl in neurons damaged by 
cisplatin. In conclusion this data illustrates that astrocytes transfer mitochondria to 
neurons damaged by cisplatin and that this transfer restores neuronal calcium 
dynamics, mitochondrial membrane potential, increases mitochondrial content and 
survival. Our findings contribute to further understanding of endogenous protective 
neuro-glial mechanisms that aid in protection of the brain against the devastating 
effects of chemotherapy on healthy cells.  
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3.8 Supplemental section: Astrocytes transfer mitochondria to neural stem 
cells 
This chapter will briefly explore the possibility of mitochondrial transfer to 
neuronal stem cells. As previously mentioned, neuronal stem cells are sensitive to 
cisplatin treatment resulting in mitochondrial dysfunction as described recently by 
Boukelmoune et al.(Boukelmoune et al., 2018c). Unlike mature neurons, 
NSCs/NPCs proliferate, which makes them a prime target for cisplatin. Moreover, 
Boukelmoune et al. and Chiu et al. found that DCX+ NPCs have decreased survival 
in the presence of cisplatin in vivo. Interestingly, Chiu et al found that unlike other 
proliferating cells that normally die after contact with cisplatin such as DCX+ NPCs, 
Nestin+/GFAP+ NSCs survive in vivo similar to mature neurons (Chiu et al., 2017c). 
This could be due to endogenous neuroprotective mechanisms such as astrocytic 
mitochondrial transfer. Boukelmoune et al. have shown that MSCs can transfer 
mitochondria to neuronal stem cells and improve mitochondrial health, but it has yet 
to be shown if astrocytes transfer mitochondria to neural stem cells. In this brief 
chapter that supplements the findings of the main chapter 3, we will show that 










Results: Astrocytes transfer mitochondria to neural stem cells 
Here we tested the hypothesis that astrocytes transfer mitochondria to neural 
stem cells damaged by cisplatin. We labeled astrocyte mitochondria with a DsRed 
plasmid targeted to the PDHA1 mitochondrial protein known as pCD510-PDHA1-
DsRed (mito-DsRed).  
NSCs were obtained commercially and were shown to mainly consist of 
DCX+ cells with only a small % of GFAP-Nestin + cells (5-15%) as shown by Flow 
analysis (Boukemoune et al.). NSCs and astrocytes were treated separately with 
cisplatin or control medium for 8 h; NSCs were labeled with Celltracker Blue, and co-
cultured with Celltracker Deep Red-labeled astrocytes for an additional 17 h. 
Confocal fluorescence analysis revealed that cisplatin-treated NSCs contained 
astrocyte-derived DsRed+ mitochondria. Very little astrocyte-derived mitochondria 
were present in untreated control NSCs co-cultured with astrocytes (Figure A & B). 
These findings indicate that astrocytes transfer mitochondria to NSCs damaged by 
cisplatin. 3D reconstruction and orthogonal section analysis confirmed that the 
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Figure 1.7: Astrocytes transfer mitochondria to neuronal stem cells. Astrocytes were 
transduced with mito-DsRed tagged to mitochondria and then stained with 
Celltracker Deep Red (artificially teal for imaging) for co-culture. Neural stem cells 
were stained with Celltracker Deep Blue. A: Astrocytes appear to transfer very little 
mitochondria to neuronal stem cells not treated with cisplatin. Right: Only red and 
teal channel to further illustrate the presence of mitochondria. B:  In the presence of 
cisplatin, astrocytes transferred mitochondria to neural stem cells. Right: Only red 
and teal channel to further illustrate the presence of mitochondria and increase in 
transfer. C, D, and E: 3-D reconstruction and orthogonal slicing showing that the 
astrocyte-derived DsRed-positive mitochondria (identified by circles in the right panel 
















This experiment illustrates that astrocytes can transfer mitochondria to neuronal 
stem cells damaged by cisplatin. Further studies are needed to explore if this 
produces potential benefits for NSC survival, but this short study provides 
preliminary evidence that astrocytes represent an endogenous protective 




















Chapter 4: Discussion 
In this dissertation I have explored if astrocytes can transfer mitochondria to 
mature cortical neurons and neuronal stem cells after cisplatin treatment. 
Additionally, we investigated whether astrocytic mitochondrial transfer to neurons 
rescues neuronal mitochondrial health. In chapter 3, our in vitro findings suggest that 
astrocytic mitochondrial transfer to neurons may represent an endogenous repair 
mechanism to counteract the neurotoxic effects of cisplatin treatment. Our evidence 
indicates that cisplatin decreases mitochondrial membrane potential in the surviving 
neurons and reduces neuronal survival. We show that co-culture of cisplatin-treated 
neurons with astrocytes results in mitochondrial transfer from astrocytes to neurons 
and is associated with restoration of neuronal mitochondrial membrane potential and 
neuronal survival. Cisplatin decreased neuronal Ca2+i levels in cortical neurons 
damaged by cisplatin. Addition of astrocytes normalized neuronal Ca2+I levels. 
Calcium levels were specifically restored in those cisplatin-treated neurons that had 
received astrocytic mitochondria. Moreover, we show that the Rho-GTPase Miro-1 is 
essential for the transfer of mitochondria from astrocytes to neurons. The siRNA-
mediated knockdown of astrocytic Miro-1 prevented the transfer of mitochondria 
from astrocytes to damaged neurons and prevented the restoration of calcium 
dynamics in neurons damaged by cisplatin. Collectively, our data support the 
hypothesis that astrocytes counteract the neurotoxic effects of cisplatin by 




In chapter 4, our in vitro findings illustrate that astrocytes can also transfer 
mitochondria to neuronal stem cells damaged by cisplatin. Though we have not 
explored if this transfer rescues the mitochondrial membrane potential,  Ca2+ 
dynamics, or NSC survival, I will discuss the results in chapter 3 in the light of the 
work done by Boukelmoune et al. who have investigated mitochondrial transfer by 
mesenchymal stem cells to neuronal stem cells treated with cisplatin(Boukelmoune 
et al., 2018c). Overall, this data supports the hypothesis that astrocytes can transfer 
mitochondria to neuronal stem cells after cisplatin treatment.  
In this chapter, I will discuss further how mitochondrial transfer could 
influence neuronal and NSC function and health, as well as the implication for 
cisplatin-induced cognitive dysfunction. I will also discuss other mechanisms that 
could be involved in regulating mitochondrial transfer that were not explored in the 
presented studies including potential signaling pathways. Another topic that will be 
touched upon are potential reasons for astrocyte resiliency to cisplatin. Moreover, I 
will discuss the translation of these in vitro findings on mitochondrial transfer to the 
importance for in vivo recovery from cisplatin-induced cognitive dysfunction. Finally, I 
will discuss future approaches to expand the study on astrocytic mitochondrial 
transfer as an endogenous protective mechanism.  
 
4.1 Implications of mitochondrial transfer on neuronal health as a result 
of cisplatin treatment: In an in vitro system we investigated whether astrocytes 
could restore neurons damaged by cisplatin treatment. To that end we pre-incubated 
neurons with cisplatin which caused a reduction in the mitochondrial membrane 
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potential in the surviving neurons and a significant decrease in neuronal survival. We 
subsequently co-cultured the surviving neurons with astrocytes that had been treated 
with cisplatin as well. The data show that astrocytes can repair existing neuronal 
damage caused by cisplatin because co-culture with astrocytes restored neuronal 
mitochondrial membrane potential and protected against further neuronal death.  
The mechanisms of how astrocytes transfer astrocytic mitochondria, repair 
neuronal mitochondrial membrane potential (MMP) or maintain survival of neurons 
are unknown. ATP hydrolysis is a possible mechanism to restore MMP. Therefore 
we hypothesize that the normalization of neuronal MMP is due to astrocytic 
mitochondria providing ATP for hydrolysis and/or astrocytic transfer of ATP or a 
combination of both(Zorova et al., 2018a).  
An important issue to address is the fate of the donated mitochondria in the 
neuronal cells. One possibility is the fusion of donor and acceptor mitochondria. 
Mitochondrial fusion is the process of mitochondria merging into the mitochondrial 
network and thus expanding the surface area for important processes such as 
oxidative phosphorylation(Hoppins, 2014; Itoh et al., 2013). The MMP must be 
sufficiently hyperpolarized for mitochondrial fusion to occur which may indicate that 
astrocytic mitochondria may integrate into the neuronal mitochondrial network 
through fusing with neuronal mitochondria after the restoration of the MMP. 
(Westermann, 2012). Furthermore, once astrocytic mitochondria are transferred and 
fused, thus improving the neuronal mitochondrial network, the damaged parts of the 
neuronal mitochondrial network may be excised during a process such as fission. 
Briefly, mitochondrial fission is the process of mitochondria fragmentation where 
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parts of the mitochondrial network are removed through an autophagic pathway or 
mitophagy (Ni et al., 2015; van der Bliek et al., 2013). Another possibility is that the 
astrocytic mitochondria do not fuse with neuronal mitochondria but act independently 
thereby improving neuronal health. 
Neuronal Ca2+ levels are tightly regulated and are critical for many processes 
in neurons including neurotransmission, depolarization, and synaptic activities. 
Mitochondria play an important role in controlling Ca2+ levels by taking up, buffering 
and releasing cytosolic Ca2+. Cisplatin can negatively alter Ca2+ levels in the dorsal 
root ganglia ((Leo et al., 2017)). Our findings expand on this knowledge by showing 
that cisplatin leads to dysfunctional cortical neuronal Ca2+ levels. Abnormalities in 
resting and KCl-evoked Ca2+ increases and clearance due to the treatment of 
cortical neurons with cisplatin were reversed in the presence of astrocytes. 
Moreover, once transfer was blocked, we saw a significant increase in abnormalities 
in resting and KCl-evoked Ca2+ dynamics. As mitochondria are important for 
neuronal Ca2+ dynamics, we suggest that astrocytic mitochondrial transfer is key to 
normalizing the neuronal mitochondrial network thereby restoring Ca2+ dynamics. It 
remains to be determined whether the normalization of Ca2+ dynamics results from a 
direct role of the donated mitochondria in calcium buffering or a secondary effect of 
donated mitochondria on other key regulators of calcium homeostasis such as the 
endoplasmic reticulum (ER), Golgi apparatus, and peroxisomes, or the functioning of 
ion channels and pumps ((Krebs et al., 2015; Luo et al., 1997; Modi et al., 2019; 
Prins & Michalak, 2011)). However, our findings do show that transfer of 
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mitochondria normalizes neuronal Ca2+ dynamics particularly in those neurons that 
are damaged by cisplatin.  
 
4.2 Implications of mitochondrial transfer on NSC health: Boukelmoune 
et al. demonstrated that mitochondrial transfer by mesenchymal stem cells could 
improve NSC mitochondrial membrane potential and survival, potentially through a 
Miro-1 dependent pathway(Boukelmoune et al., 2018c). We expanded upon the idea 
of mitochondrial transfer to NSCs by exploring the possibility of endogenous 
protection through astrocytic mitochondrial transfer to NSCs in vitro (chapter 4).  
An interesting point of discussion is that during cisplatin treatment Chiu et al. 
have shown that the number of (DCX+) NPCs decreases in vivo, whereas other 
studies showed that this is not necessarily the case for NSCs (Nestin+/GFAP+)(Chiu 
et al., 2017a, 2018a). This brings up the question if astrocytes protect NSCs from 
cell death during cisplatin damage in vivo. We speculate that astrocytes may 
preferentially promote the health of the non-lineage specific NSCs which could give 
rise to new neurons and glial cells rather than the lineage-specific NPCs. Moreover, 
NSCs may have a higher regenerative capacity and capability to repair damage in 
the brain and thus may be deemed as needing more protection for maintaining the 
survival/function of the essential mature neurons.  
Due to the GFAP+ nature of NSCs in the adult brain, some have argued that 
this is a subset of astrocytes(Ihrie & Alvarez-Buylla, 2008a; Kriegstein & Alvarez-
Buylla, 2009a). Along this vein, it could be that like mature astrocytes, this subset 
may be resistant to cisplatin. However, at least in vitro, there is some indication that 
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NSCs are sensitive to cisplatin despite not dying in vivo (similar to the findings for 
mature neurons)(Boukelmoune et al., 2018c; Chiu et al., 2017a). However, we have 
to keep in mind that there may be a gradual sensitivity defined by the fact that 
although there is no clear loss of NSCs after cisplatin in vivo, the mitochondrial 
function of NSC might still be in need of repair by astrocytic mitochondria.  
 
4.3 Mechanisms of mitochondrial transfer: TNTs, Miro-1, Myo10, and 
CD38: A structural transport mechanism that has been shown to be involved in 
intercellular mitochondrial transfer are tunneling nanotubes (TNTs). TNTs are thin 
non-adherent actin-rich membranous structures with diameters between 50-1500 nm 
that can span long distances of several hundred nm ((Abounit et al., 2015; Babenko 
et al., 2018a; Boukelmoune et al., 2018c; Gousset et al., 2013; Las & Shirihai, 
2014a; Vignais et al., 2017; Y Wang et al., 2011b)). These TNTs form direct 
connections between cells to transport cellular components including cytoplasm, 
ions, lipid droplets, viral and bacterial pathogens, genetic material and organelles 
like lysosomes, and last but not least, mitochondria ((Astanina et al., 2015; C. J. Li et 
al., 2017; Vignais et al., 2017)). Multiple authors have described that the 
mitochondrial Rho-GTPase-1 protein (Miro-1) is a crucial player in intercellular 
mitochondrial transfer. Miro-1 is an outer mitochondrial membrane protein, that binds 
to Milton, a kinesin/dynein adaptor protein and this promotes mitochondrial 
motility((Kalinski et al., 2019b; K. S. Lee & Lu, 2014; Melkov et al., 2016; Schwarz, 
2013b)). We have now expanded this knowledge by showing that decreasing Miro-1 
expression in astrocytes decreased the transfer of mitochondria from astrocytes to 
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damaged neurons. Apparently, astrocytic Miro-1 is required for transfer of astrocyte 
mitochondria to neurons.  
In terms of molecules that initiate TNT formation, it has been described by 
Gousset et al. that Myo10, molecular motor myosin-X) plays a role in TNT formation 
in neuronal CAD cells(Gousset et al., 2013). Through overexpression and 
knockdown studies, they were able to show that Myo10 had a direct effect on TNT 
formation and function of TNTs including transportation of vesicles. Though Gousset 
et al. studied Myo10 in neuronal cells, it should be noted that Myo10 has a higher 
expression in astrocytes than in neurons which could further imply that TNT 
formation is mostly executed by astrocytes(Brain RNA-Seq, n.d.-a).  
Jiang et al. have described that the cyclic ADP ribose hydrolase CD38 plays 
an important role in astrocytic mitochondrial transfer((D. Jiang et al., 2016)). CD38 
plays several roles in astrocyte maturation and overall health, including 
differentiation of astrocytes (Hattori et al., 2017a). Inhibition of CD38 with apigenin 
significantly reduced astrocytic mitochondrial transfer and it has been suggested that 
CD38 may be involved in TNT formation ((Marlein et al., 2019)). Furthermore, in an 
in vitro myeloma cancer model, myeloma cells were shown to receive mitochondria 
from non-malignant bone marrow stromal cells through CD38-dependent tumor-
derived formation of TNTs ((Marlein et al., 2019)). However, we have to keep in 
mind that this CD38 mediated phenomenon could be specific for tumor cells. It could 
also be the case that CD38 may play a more direct role in mitochondrial transfer as 
shown by Hayakawa et al., where knockdown of CD38 led to a direct decrease in 
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mitochondrial transfer(Hayakawa et al., 2016b). This could also be the case for our 
model.  
 
4.4 Potential signaling mechanisms involved: Our data show that 
astrocytes transfer mitochondria to neurons and NSCs damaged by cisplatin while 
there is only very limited transfer under control conditions.  Similarly, we have 
reported previously that mesenchymal stem cells transfer more mitochondria to 
neuronal stem cells (NSCs) damaged by cisplatin than to control NSCs 
(Boukelmoune et al., 2018c). Hayakawa et al. showed that astrocytes transfer more 
mitochondria to damaged neurons in an ischemic stroke model in comparison to 
control in vitro and in vivo(Berridge et al., 2016). The differences in transfer could 
indicate existence of a damage signal that neurons or NSCs express or release that 
initiates astrocytic mitochondrial transfer. We hypothesize that astrocytes may 
respond to a “help” signal that is expressed by damaged neurons leading to the 
transfer of mitochondria. It has been suggested that the accumulation of p53 on 
damaged mitochondrial membranes and/or the release of  Damage-Associated 
Molecular Patterns (DAMPS) could serve as the “help” signal (Y Wang et al., 2011a) 
(Vichaya et al., 2015a; Wilkins et al., 2017).  Further studies are needed to identify 
which signals initiate the transfer process.  
 
4.5 Astrocyte resiliency: Our cell survival studies showed that astrocytes 
are much less sensitive to cisplatin than neurons. Chiu et al. also did not find a 
decrease in GFAP+ astrocytes in vivo after treating mice with cisplatin(Chiu et al., 
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2017a, 2018a). This is an interesting finding because astrocytes are mitotic and thus 
could be a prime target of cisplatin toxicity. Moreover, since astrocytes assist in 
forming the blood-brain barrier and are the most abundant cell type in the brain, it 
could be possible that they are exposed to higher concentrations of cisplatin in 
comparison to other cell types such as neurons. These findings could mean that 
astrocytes could have a way of removing cisplatin before significant damage can 
occur to nDNA or mtDNA. RNA-seq data ((Brain RNA-Seq, n.d.-b)), show that 
astrocytes have a higher concentration of the mitochondrial polymerase gamma 
(pol-γ) in comparison to neurons which is the sole polymerase involved in 
mitochondrial replication, mutagenesis, and repair of mtDNA. Therefore, we suggest 
that the relatively high activity of pol-γ in astrocytes may lead to efficient repair of 
cisplatin adducts which could contribute to the observed astrocytic resiliency. ATP7a 
and ATP7b are copper transporters that also promote platinum efflux and thereby 
may contribute to cellular resistance to cisplatin ((Blair et al., 2009a; Kilari et al., 
2016a; Kuo et al., 2007)). Astrocytes have a higher concentration of these copper 
transporters ATP7a and ATP7b in comparison to neurons and other glial cells 
((Brain RNA-Seq, n.d.-b)). Astrocytes also have dynamic and efficient 
metabolism(Bouzier-Sore & Pellerin, 2013; Morita et al., 2019b). Though astrocytes 
rely on oxidative phosphorylation, they also have a robust glycolytic capacity 
including glycogen metabolism, and they can dynamically switch the degree of 
usage from these energy sources(Morita et al., 2019a). It could also be possible that 
during cisplatin insults astrocytes predominantly use a glycolytic pathway which 
could then lessen the pressure on mitochondrial oxidative phosphorylation and allow 
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more efficient repair of the mitochondria from cisplatin toxicity. Taken together, we 
propose that astrocytes could use a variety of mechanisms to remain resilient to 
cisplatin and further studies would be needed to understand astrocytic resiliency.  
 
4.6 Translatability of the model: An in vitro system was the most optimal 
method of selectively investigating the effects of astrocytic mitochondrial transfer on 
mature neurons and NSCs in the presence of cisplatin. This system allowed us 
efficient observations in measuring survival, mitochondrial membrane potential, 
transfer, and Ca2+ dynamics. As with all in vitro systems, there is the question of how 
relatable the model is to what occurs in vivo in the human brain.  
For our model, a persistent question is if the dosage of cisplatin is 
comparable to what could accumulate in the human brain. Stewart et al. found that 
in patients treated with 40-220 mg/m2 intravenously or by intracarotid infusion 0-180 
days before analysis platinum concentrations in the brain varied from 0.33-2.97 
µg/g(Stewart et al., 1994a). Hermann et al. illustrated that in cell cultures treated with 
5 µM cisplatin, intracellular platinum accumulation varied between 1.3-5.5 µg/g, 
which is within range of the concentration found by Stewart et al.(Andres et al., 
2014a; Hermann et al., 2013). Our model uses 1µM cisplatin (similar to the 
concentration used by Boukelmoune et al. and Andres et al.), which is a much lower 
dose(Andres et al., 2014a; Boukelmoune et al., 2018c). From this information, we 
can speculate that if 5 µM provides an intracellular concentration of 1.3-5.5 µg/g and 
this is within range of what has been found in the human brain, our dose of 1µM 
would be a dose with clinical relevance. Therefore, we propose that 1µM is a 
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relevant and translatable dose, and thus provides a realistic understanding of what 
could occur in vivo in the human brain.  
An important translational question still lingers: if astrocytic mitochondrial 
transfer occurs in the brain after cisplatin treatment, why do patients undergoing 
chemotherapy still experience neurotoxicity leading to chemotherapy-induced 
cognitive impairment?  One argument could be that the relatively long duration of 
cisplatin treatment of patients would decrease the endogenous restorative capacity 
of astrocytes. Indeed, the risk of developing chemobrain increases with duration of 
treatment((Asher, 2011; Gutmann, 2019b; T. Jiang & Cadenas, 2014; Ren et al., 
2019; X. M. Wang et al., 2015a)). Moreover, our preliminary data indicate that 
exposure of mice to a single round of cisplatin treatment does not induce cognitive 
deficits, whereas two rounds of cisplatin do induce significant decreases in 
performance in tests of cognitive function ((Chiu et al., 2017a; W. Zhou et al., 
2016a)). 
 The endogenous protective activity of transferring healthy mitochondria from 
astrocytes to damaged neurons may also become less efficient in the aging 
brain(Morita et al., 2019a; Palmer & Ousman, 2018). The severity of the behavioral 
neurotoxic effects is correlated with age ((Asher, 2011; Gutmann, 2019a)). We also 
know that the majority of cancer cases occur in people aged 65 and over (Risk 
Factors: Age - National Cancer Institute, n.d.; White et al., 2014). When endogenous 
protective mechanisms are no longer sufficient, therapeutic interventions aimed at 
restoring mitochondrial health will be needed. In this respect it is of interest that 
exogenous cell therapy with mesenchymal stem cells or a pharmacological 
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intervention with an HDAC6 inhibitor both reverse cisplatin-induced neuronal 
mitochondrial abnormalities as well as cognitive impairment in mice ((Chiu et al., 
2017a, 2018a; Kalinski et al., 2019a; J. Ma, Huo, et al., 2018; Van Den Bosch, 2019; 
Vichaya et al., 2015b)).  
 
4.7 Future directions and concluding remarks: It will be important to 
explore the fate of donated mitochondria once they are transferred to the neurons. 
We hypothesized that the donated mitochondria would fuse with the neuronal 
mitochondrial network. This hypothesis should be tested by transfecting neurons 
with a mitochondrial marker and co-culturing them with astrocytes. Higher 
magnification or possibly super-resolution microscopy would allow us to observe if 
the astrocytic mitochondria fuse with the neuronal mitochondrial network. This could 
provide some explanation of what occurs after transfer and could represent one 
explanation for the beneficial effects observed. Furthermore, it would be interesting 
to observe the direct exchange and movement of donated mitochondria through 
time-lapse imaging. For this experiment it may be advantageous to exchange the 
plasmid used in chapter 3 for the lentiviral plasmid used in the supplemental section 
with the reasoning that the lentiviral plasmid would have a higher mitochondrial 
transfection efficiency. We could then use high resolution microscopy and time-lapse 
imaging to observe transfer and possibly be able to quantify the mitochondrial 
content that is transferred.  
Another worthwhile question would be if astrocytes transfer mitochondria to 
neurons and NSCs (or NPCs) damaged by cisplatin in vivo. This could be done by 
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creating a transgenic mouse that has tagged astrocytic mitochondria. One option is 
to cross a GFAPcre (or another strain that targets specifically a large population of 
astrocytes) with a PhAMfloxed mouse(018385 - B6;129S-Gt(ROSA)26Sor<tm1(CAG-
COX8A/Dendra2)Dcc>/J, n.d.; 024098 - B6.Cg-Tg(Gfap-cre)77.6Mvs/2J, n.d.). This 
mouse expresses a mitochondrial specific version of Dendra2, which is a 
photoswitchable, monomeric fluorescent protein derived from octocoral(Pham et al., 
2012). We would then treat this mouse with cisplatin following established protocols 
previously used by our group and observe if there is a difference between treated 
and untreated groups in terms of astrocytes transferring mitochondria to neurons.  
Two potential results could arise with an in vivo model: (1) We could observe 
whether transfer occurs in all areas of the brain in the cisplatin-treated model or (2) 
whether mitochondrial transfer is restricted to specific regions. We propose that 
mitochondrial transfer could happen in all brain regions that are damaged by 
cisplatin. When we accept that Damps or mitochondrial p53 represent (one of the) 
damage signals, it would imply that astrocytic mitochondrial transfer may be a more 
general phenomenon since many cell types express Damps or mitochondrial p53 
after damage. This means that transfer could occur in response to many types of 
stressors or insults, not just cisplatin.  
Still it is difficult to conclude that mitochondrial transfer is a general protective 
phenomenon since the majority of transfer experiments have been done in vitro with 
either hippocampal cells or cortical cells, and the one in vivo experiment by 
Hayakawa et al. was also focused on the cortex(Hayakawa et al., 2016a). Taken 
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together, we propose that in vivo experiments would be necessary to further explore 
the mechanisms of astrocytic mitochondrial transfer. 
Further experiments would be necessary to explore how astrocytic 
mitochondrial transfer could improve NSC health as well. Based on Boukelmoune’s 
data, we could explore if mitochondrial transfer from astrocytes improves NSC/NPC 
survival and mitochondrial membrane potential following similar protocols that were 
used for Chapter 3. In terms of calcium dynamics we would investigate how cisplatin 
effects Ca2+ in NSCs/NPCs and if astrocytes provide a restorative effect. We could 
also explore if knockdown of Miro-1 activity in astrocytes could decrease transfer 
and abrogate the potential health benefits of mitochondrial transfer. 
 
To conclude, my dissertation expands upon the fascinating mechanism of 
astrocytic mitochondrial transfer as a protective and restorative process of neuronal 
mitochondrial health. I have also shown that this process can occur in the presence 
of cisplatin, a common but toxic chemotherapeutic that is known to be the cause of 
cognitive dysfunction. Briefly, I have discussed the investigation that astrocytic 
mitochondrial transfer to neurons improves neuronal mitochondrial membrane 
potential, Ca2+ dynamics, and survival. Miro-1 appears to play a vital role in 
astrocytic mitochondrial transfer and blocking astrocytic Miro-1 abrogates the 
beneficial effects. Furthermore, I have discussed the investigation of if astrocytes 
transfer mitochondria to NSCs, another important neuronal cell type, and a process 
that has yet to be observed in the literature. Ultimately, my findings provide evidence 
for an important endogenous protective neuro-glial mechanism that could contribute 
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to the prevention of neuronal death as a result of cisplatin treatment and thereby aid 
in sustaining brain health of patients during chemotherapy. Furthermore, I can 
envision that our findings will be important for others in the field of neuroscience to 
explore this neuroprotective and regenerative neuro-glial mechanism in other 
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